Results for tag: Martin Schuler
Total Items Found: 2
Order By Item Count
Order Alphabetically
-
16 gene recurrence score (1)
-
177Lu-DOTATATE (1)
-
17p deletion (1)
-
18F-fluciclovine PET/CT (1)
-
2015 Palliative Care in Oncology (16)
-
2016 ASTRO Annual Meeting (16)
-
2016 GI Cancers Symposium (15)
-
2016 NCCN Annual Meeting (21)
-
2016 NCCN Annual Meetng (1)
-
2016 NCCN guidelines (1)
-
2016 Palliative Care in Oncology (16)
-
2016 Quality Care Symposium (17)
-
2016 Survivorship Symposium (14)
-
2017 Cancer Survivorship Symposi (1)
-
2017 Quality Care Symposium (1)
-
2017 San Antonio Breast Cancer S (1)
-
21 gene score (1)
-
21-gene recurrence score (1)
-
21st Annual NCCN Conference (1)
-
3-D conformal radiation (1)
-
4R model (1)
-
5-fluorouracil (1)
-
5FU (1)
-
5-FU (1)
-
5HT3 antagonist (1)
-
5HT3 receptor (1)
-
7+3 chemotherapy (1)
-
A. Collier Smyth (1)
-
A. Craig Lockhart (2)
-
A. Kate Macdougall (4)
-
A. Oliver Sartor (5)
-
aacr 2020 (10)
-
AACR Covid and Cancer (7)
-
aacr virtual annual meeting (1)
-
AACR Virtual II (12)
-
Aakash Desai (1)
-
Aaksh Desai (2)
-
Aalaa Mahmoud (1)
-
Aaron Martin (1)
-
Aaron Sasson (1)
-
AARON TALLENT (2)
-
Abby B. Sandler (1)
-
Abby Rosenberg (1)
-
ABCSG trial (1)
-
ABCSG-16 trial (1)
-
ABCSG-18 (1)
-
ABCSG-18 trial (1)
-
abemaciclib (3)
-
abiraterone (9)
-
abiraterone acetate (6)
-
ablation (1)
-
Abramson Cancer Center (3)
-
abscopal responses (1)
-
ABVD chemotherapy (1)
-
AC (2)
-
aca (2)
-
academic cancer center (1)
-
academic health centers (1)
-
academic hospital (1)
-
acalabrutinib (1)
-
acalabrutinib, asco 2019, chronic lymphocytic leukemia, cll, obinutuzumab (1)
-
ACCC (5)
-
accelerate treatment (1)
-
accelerated fractionation radiot (1)
-
access (2)
-
access to care (2)
-
access to opioids (1)
-
ACCORD12 trial (2)
-
ACCRU trial (1)
-
ace-536 (1)
-
activated RAS (1)
-
active cancer surveillance (1)
-
active surveillance (1)
-
active symptom control (1)
-
active treatment (1)
-
ACTIVE8 trial (1)
-
acts-cc 02 trial (1)
-
acupuncture (2)
-
acute care (1)
-
acute lymphoblastic leukemia (8)
-
acute lymphocytic leukemia (1)
-
acute myeloblastic leukemia (1)
-
acute myeloid leukemia (14)
-
acute toxicity (1)
-
Adam Brufsky (1)
-
Adam Hayden (1)
-
Adam Metwalli (1)
-
Adam Stern (1)
-
Adam Sutton (1)
-
ADAPT trial (1)
-
adc (1)
-
adcs (1)
-
adenocarcinoma (4)
-
adipocytic sarcoma (1)
-
adipokines (1)
-
adjustment disorders (1)
-
adjuvant (10)
-
adjuvant analgesics (1)
-
adjuvant chemotherapy (11)
-
adjuvant docetaxel (1)
-
adjuvant endocrine therapy (3)
-
adjuvant endocrine treatment (1)
-
adjuvant endorcine therapy (1)
-
adjuvant hipec (1)
-
adjuvant radiotherapy (2)
-
adjuvant therapy (6)
-
adjuvant treatment (3)
-
adolescent cancer (1)
-
adolescent cancer survivor (1)
-
adolescent oncology (1)
-
adolescent survivor (1)
-
adolescents (1)
-
Adolfo González Serrano (1)
-
adoptive cell therapy (1)
-
ado-trastuzumab emtansine (1)
-
adriamycin (1)
-
Adrienne Boissy (1)
-
Adrienne R. Boissy (1)
-
Adrienne Scheck (1)
-
ADT (9)
-
adult ALL (1)
-
adult cancer (1)
-
advance care planning (1)
-
advance of the year (1)
-
advanced bladder cancer (1)
-
advanced breast cancer (7)
-
advanced cancer (9)
-
advanced cancer care (1)
-
advanced colorectal cancer (1)
-
advanced disease (3)
-
advanced lung cancer (3)
-
advanced lymphoma (1)
-
advanced melanoma (2)
-
advanced NSCLC (2)
-
advanced phase leukemia (1)
-
advanced practice nurse (1)
-
advanced prostate cancer (1)
-
advanced refractory cancer (1)
-
advanced solid tumor (1)
-
advanced urothelial carcinoma (1)
-
advanced-stage disease (1)
-
advances in therapy (1)
-
adverse events (9)
-
advocacy (1)
-
advocate (1)
-
aethera trial (1)
-
afatinib (6)
-
affordability (2)
-
affordability of care (1)
-
affordable care (1)
-
Affordable Care Act (3)
-
affordable drug initiative (1)
-
African American (2)
-
African Americans (1)
-
age 40 (1)
-
age 50 (1)
-
agent-based therapy (2)
-
aggressive lymphomas (1)
-
aggressive medical care (1)
-
aggressive myeloma (1)
-
aggressive therapy (1)
-
aggressive treatment (2)
-
aging population (1)
-
agnostic therapy (1)
-
AHCT (3)
-
AHMED ELHAJ (1)
-
AI (1)
-
Aichi Cancer Center Hospital (1)
-
AIO trial (1)
-
Aix Marseille University (2)
-
Ajay Nooka (2)
-
Ajeet Gajra (1)
-
Aju Mathew (1)
-
Akila Viswanathan (1)
-
akt1 mutation (1)
-
akt3 (1)
-
Al Benson (3)
-
Alain Ravaud (2)
-
alan f. list (8)
-
Alan List (2)
-
Alan Pollack (1)
-
Alan Venook (2)
-
Albert Deisseroth (1)
-
Alcala de Henares University (1)
-
ALCHEMIST (1)
-
ALCYONE trial (1)
-
Alec Kupelian (1)
-
alectinib (3)
-
Aleix Prat (2)
-
Alejandro Chaoul (1)
-
Alejandro Salicrup (1)
-
ALESIA (1)
-
Alessandra Tedeschi (2)
-
Alex Carney (1)
-
Alex Carolan (3)
-
Alex Francisco Herrera (1)
-
Alex Herrera (1)
-
Alex Sieg (1)
-
ALEX trial (1)
-
Alexander Andreev-Drakhlin (1)
-
Alexander Eggermont (1)
-
Alexander N. Shoushtari (1)
-
Alexander Pine (1)
-
Alexander R. Ende (1)
-
Alexander van Akkooi (1)
-
Alexandra Maertens (1)
-
Alexandra Vitale (1)
-
Alexis Browning (1)
-
ALFA/Clara (1)
-
Alfred Lee (1)
-
Alfred Neugut (1)
-
algorithm (1)
-
Ali Raza Khaki (1)
-
Alice Chung (2)
-
Alice Goodman (1485)
-
Alice Goodman and Caroline Helwick (3)
-
Alice Mims (1)
-
Alice Shaw (5)
-
Alice Tsang Shaw (2)
-
Aline Charabaty (1)
-
Aline Fusco Fares (1)
-
Alison Jefferies (1)
-
Alison Loren (2)
-
ALK (4)
-
ALK fusion (1)
-
ALK inhibitors (1)
-
ALK positive (2)
-
ALK testing (1)
-
ALL (12)
-
Allan Espinosa (1)
-
Allegheny General Hospital (1)
-
Allen Lichter (9)
-
alliance (1)
-
ALLIANCE A031201 trial (1)
-
ALLIANCE A031203 trial (1)
-
Alliance trial (2)
-
Allison Applebaum (9)
-
Allison Harvey (1)
-
Allison Kurian (1)
-
Allison Magnuson (1)
-
Allison Rosen (1)
-
allogeneic hematopoietic cell tr (4)
-
allogeneic stem cell transplanta (2)
-
Alok Khorana (2)
-
alopecia (2)
-
alpelisib (1)
-
ALSYMPCA trial (1)
-
ALTERNATE trial (1)
-
Aly-Khan Lalani (1)
-
Alysa Fairchild (2)
-
Aman Buzdar (1)
-
Amanda Blair (1)
-
Amanda J. Redig (1)
-
Amanda McIntyre (1)
-
Amanda Narod (3)
-
ambulatory (1)
-
Amelie Harle (2)
-
Amer Zeidan (1)
-
American cancer disparities (1)
-
American Cancer Society (7)
-
American Indian (1)
-
American Indians (1)
-
American Medical Association (1)
-
American Society for Radiation O (1)
-
american society of hematology (31)
-
american society of hematoly (1)
-
American University of Beirut (1)
-
Ami Chitalia (1)
-
Amina Ahmed (1)
-
Aminah Jatoi (1)
-
Amir Steinberg (1)
-
Amit Kulkarni (1)
-
Amit Mahipal (1)
-
Amitabh Gulati (1)
-
AML (18)
-
Amy Cyr (2)
-
Amy Kiamos (1)
-
Amy MacKenzie (3)
-
Amye Tevaarwerk (1)
-
Ana I. Tergas (1)
-
Ana Maria López (1)
-
Anahid Hamparsumian (1)
-
anal squamous cell cancer (1)
-
anamorelin (3)
-
anaplastic (1)
-
anaplastic glioma (1)
-
anaplastic oligodendroglioma (1)
-
Anas Younes (3)
-
anastrozole (11)
-
and L. Jeffrey Medeiros (1)
-
andecaliximab (1)
-
Anders Widmark (1)
-
Andrea Ferrari (1)
-
Andrea Lim (1)
-
Andrea Patenaude (1)
-
Andrea Watson (2)
-
Andreas Engert (3)
-
Andreas Hochhaus (1)
-
Andreas Rimner (1)
-
Andrew Armstrong (6)
-
Andrew Chapman (1)
-
Andrew Chi (1)
-
Andrew Clamp (1)
-
Andrew Davies (2)
-
Andrew Dunbar (1)
-
Andrew Evens (2)
-
ANDREW HAHN (1)
-
ANDREW HERTLER (1)
-
Andrew James Martin (3)
-
Andrew Ko (2)
-
Andrew Martin (1)
-
Andrew Roth (2)
-
Andrew S. Epstein (1)
-
Andrew Seidman (24)
-
Andrew Zelenetz (10)
-
Andriy Hrynkiv (1)
-
androgen deprivation (3)
-
androgen deprivation therapy (6)
-
androgen receptor (1)
-
androgen receptor-positive (1)
-
androgen suppression (1)
-
androgen-deprivation therapy (7)
-
androgens (1)
-
Andy Lindsay (1)
-
Anees Chagpar (2)
-
anemia (2)
-
anesthetics (1)
-
Angela Bradbury (1)
-
Angela Pang (1)
-
angiosarcoma (1)
-
Anil D'Cruz (2)
-
Anil Sood (1)
-
Animesh Pardanani (1)
-
Anis Hamid (1)
-
Anita D'Souza (2)
-
Anita Mahajan (2)
-
Anita O'Donovan (1)
-
Anjali Advani (1)
-
Ann Farrell (1)
-
Ann Graham (1)
-
ann h. partridge (1)
-
Ann Klopp (1)
-
Ann Partridge (8)
-
Ann Ramer (1)
-
Anna Patrikidou (1)
-
Anna Rachelle Mislang (1)
-
Anne Blaes (2)
-
Anne Chiang (1)
-
Anne Covey (1)
-
Anne Jacobs (1)
-
Anne Katz (1)
-
Anne Kimha (1)
-
Annick Desjardins (1)
-
Annie Howell (1)
-
Ann-Lii Cheng (1)
-
announce trial (1)
-
anorexia (3)
-
Anschutz Cancer Pavilion (1)
-
Anthony Back (3)
-
ANTHONY D’AMICO (1)
-
Anthony D'Amico (3)
-
Anthony Olszanski (11)
-
Anthony Perre (1)
-
Anthony Zietman (6)
-
anthracycline (3)
-
anthracycline-based chemotherapy (1)
-
antiandrogen therapy (2)
-
anti-androgen therapy (1)
-
antiangiogenic (1)
-
antiangiogenic agent (1)
-
anti-B-cell maturation antigen (1)
-
antibiotics (1)
-
antibody blockade (1)
-
antibody drug conjugate (1)
-
antibody IMAB362 (2)
-
antibody-drug conjugate (2)
-
anti-CD19 (2)
-
anti-CD19 monoclonal antibody (1)
-
anti-CD22 (1)
-
anticoagulation (1)
-
anticonvulsant (1)
-
anti–CTLA-4 (1)
-
antidepressant agents (1)
-
antiestrogen therapy (1)
-
anti-GD2 (2)
-
anti-PD-1 (1)
-
anti–PD-1 (3)
-
anti–PD-L1 (1)
-
anti-PD-L1 antibody (1)
-
anti-PLD1 monoclonal antibody (1)
-
antipsychotic (1)
-
antitumor effect (1)
-
antitumor immunity (1)
-
anti-VEGF (1)
-
Anton Barchuk (1)
-
Antonio C. Wolff (1)
-
Antonio Castaneda (2)
-
Antonio Palumbo (2)
-
anxiety (6)
-
ANZUP (3)
-
apact (1)
-
apalutamide (2)
-
Apar Kishor Ganti (4)
-
apatorsen (1)
-
APHINITY trial (1)
-
APL (1)
-
app (2)
-
aprepitant (3)
-
Aram Demirjian (1)
-
aramis trial (2)
-
Arash Asher (1)
-
ARCHER 1050 (1)
-
ARCHER 1050 trial (1)
-
Areej El-Jawahri (3)
-
ARIEL3 (1)
-
Arielle Elkrief (2)
-
Arizona Breast Cancer Specialist (1)
-
Arjun Balar (1)
-
Arjun Patel (1)
-
Arjun Vasant Balar (1)
-
arm mobility (1)
-
Armando Armas (1)
-
Armando E. Giuliano (2)
-
Armando Giuliano (1)
-
Armando Sardi (1)
-
Armitage (1)
-
Arnaud Scherpereel (2)
-
aromatase inhibitor (12)
-
aromatase inhibitors (4)
-
arrow trial (1)
-
arsenic (1)
-
Artemis Health Institute (1)
-
Artemis Hospitals (1)
-
arterial-directed therapy (1)
-
arthralgia (1)
-
Arti Hurria (3)
-
artificial intelligence (1)
-
Asan Medical Center (1)
-
ASCEND-5 trial (1)
-
ascend-7 (1)
-
ASCENDE-RT (1)
-
ASCO (1358)
-
ASCO 2015 (53)
-
ASCO 2016 (63)
-
ASCO 2017 (55)
-
ASCO 2018 (67)
-
asco 2019 (69)
-
asco 2019, breast cancer, capecitabine, her2-positive, lapatinib, metastatic, nala trial, neratinib (1)
-
ASCO Choosing Wisely (1)
-
ASCO Communications (3)
-
ASCO Connection (1)
-
ASCO Palliative Care (12)
-
asco post (51)
-
ASCO President (2)
-
ASCO Publishing (1)
-
ASCO Quality Care (11)
-
ASCO Quality Care 2017 (13)
-
asco quality training program (1)
-
asco sitc (19)
-
ASCO Virtual Scientific Program (1)
-
ASCO20 (49)
-
ASCO-ECCO (1)
-
ascoo 2019 (1)
-
ASCO-SITC 2017 (11)
-
ASCT (3)
-
ASH (5)
-
ASH 2015 (33)
-
ASH 2016 (25)
-
ASH 2017 (11)
-
ASH 2018 (18)
-
ash 2020 (1)
-
ash annual meeting (48)
-
Asher Chanan-Khan (3)
-
Ashfaq Marghoob (1)
-
Ashley Cimino-Mathews (1)
-
Ashley Wysong (1)
-
Asian (1)
-
aspire trial (1)
-
aspirin (2)
-
assays (1)
-
Assistance Publique Hopitaux De (1)
-
assisted suicide (1)
-
Association of Community Cancer (1)
-
ASTRO (2)
-
ASTRO 2015 (19)
-
ASTRO 2017 (12)
-
ASTRO 2018 (11)
-
astro 2020 (9)
-
astro annual meeting (14)
-
atempt trial (1)
-
atezolizumab (24)
-
Athalia Rachel Pyzer (1)
-
Atiqur Rahman (1)
-
atra (1)
-
AUA (1)
-
AUGMENT trial (1)
-
AUGUSTO LEÓN (1)
-
Aurelius Omlin (1)
-
autoimmune disease (2)
-
autologous hematopoietic cell tr (1)
-
autologous stem cell transplant (6)
-
autologous transplantation (1)
-
autonomic imbalance (1)
-
avasopasem manganese (1)
-
avelumab (5)
-
Avni Desai (1)
-
Avraham Eisbruch (1)
-
Avrum Bluming (2)
-
Axel Grothey (9)
-
axicabtagene ciloleucel (2)
-
axillary lymph node dissection (1)
-
axitinib (6)
-
AYA cancer (2)
-
AYA oncology (3)
-
AYA survivors (1)
-
ayalew tefferi (6)
-
Ayesha Munir (1)
-
azacitidine (6)
-
AZD5363 (1)
-
Azienda Ospedaliera Niguarda Cà (1)
-
B.J. Rimel (1)
-
B-40 trial (1)
-
B-51 trial (1)
-
Babara Gitlitz (1)
-
baf-type (1)
-
Bahar Javdan (1)
-
Bain Capital Life Sciences (1)
-
BALKEES ABDERRAHMAN (1)
-
b-all (1)
-
Barb Young (1)
-
Barbara Boughton (3)
-
Barbara Gitlitz (1)
-
Barbara K. Rimer (1)
-
Barbara McAneny (2)
-
Barnardo Rapoport (1)
-
Barnett Kramer (2)
-
Barrie Cassileth (21)
-
Barrie R. Cassileth (1)
-
barriers to care (1)
-
barriers to quality (1)
-
Barry Paul (1)
-
Barts Cancer Institute (2)
-
Barts Health NHS Trust (2)
-
basal cell carcinoma (2)
-
basal type breast cancer (1)
-
basic science (1)
-
basket trial (1)
-
basket trials (1)
-
Bates Moses (1)
-
Baylor College of Medicine (5)
-
BC2001 trial (1)
-
B-cell ALL (3)
-
B-cell lymphoma (2)
-
B-cell malignancies (1)
-
B-cell non-Hodgkin lymphoma (1)
-
B-cell precursor (1)
-
BCG (1)
-
BCIRG-006 study (1)
-
bcl-2 (1)
-
bcl2 inhibitor (1)
-
BCMA (1)
-
BEACON CRC (2)
-
Beat Thürlimann (1)
-
Beatriz Korc-Grodzicki (1)
-
BELIEF trial (1)
-
BELLE-3 trial (1)
-
Bellinda King-Kallimanis (1)
-
bendamustine (9)
-
bendustamine (1)
-
Benjamin Anderson (1)
-
Benjamin Besse (2)
-
Benjamin Movsas (1)
-
Benjamin Smith (4)
-
Benyam Muluneh (1)
-
benzodiazepines (1)
-
Bernard Escudier (7)
-
Bernard Fisher (2)
-
Bernardo Rapoport (1)
-
Bertrand Coiffier (6)
-
Bertrand Routy (1)
-
best care (1)
-
Best of ASCO (1)
-
beta-thalassemia (1)
-
Beth Faiman (1)
-
Beth Fairchild (1)
-
Beth Howard (3)
-
Beth Israel Deaconess (1)
-
Beth McLellan (1)
-
BETTY DICKER (1)
-
Betty Ferrell (2)
-
Betty Hamilton (1)
-
bevacizumab (29)
-
Beverly Canin (1)
-
Beverly Vuckovich (1)
-
BGB-290 (1)
-
BGB-A317 (1)
-
BGJ398 (1)
-
Bhavana Konda (1)
-
Bhishamjit Chera (1)
-
Bhuvanesh Singh (1)
-
bicalutamide (4)
-
big data (3)
-
bilateral (1)
-
bilateral mastectomy (1)
-
BILCAP trial (1)
-
bile duct cancer (1)
-
biliary cancer (1)
-
biliary tract cancer (6)
-
Bill Brummel (1)
-
Bill Gradishar (1)
-
Bill McClain (1)
-
Bin McLaurin (1)
-
binimetinib (2)
-
biochemical control (1)
-
biochemical failure (1)
-
biochemical recurrence (1)
-
biochemical relapse (1)
-
biologics (1)
-
biology in younger patients (1)
-
biology of pain (1)
-
biomarker (13)
-
biomarker stratification (2)
-
biomarkers (10)
-
biopsy (2)
-
biosimilar (1)
-
biosimilars (4)
-
Biosimilars (1)
-
biphosphonate treatment (1)
-
BIRCH trial (1)
-
biscay trial (1)
-
Bishal Gyawali (1)
-
Bishoy Faltas (5)
-
bisphophonates (1)
-
BITE (1)
-
black patients (2)
-
bladder cancer (40)
-
Bladder Cancer (20)
-
bladder preservation (1)
-
Blase N. Polite (1)
-
Blase Polite (1)
-
blast phase (1)
-
bleomycin (1)
-
blinatumomab (4)
-
blinatumumab (1)
-
blood biomarker (1)
-
blood cancer (1)
-
blood-brain barrier (2)
-
blu-667 (1)
-
Bob Carlson (2)
-
Bob Levis (1)
-
Bobby Daly (1)
-
body composition (2)
-
body image (1)
-
BOLERO-2 (1)
-
BOLERO-4 (1)
-
bone fractures (1)
-
bone marrow transplant (1)
-
bone metastases (3)
-
Bonnie Addario (1)
-
Bonnie Glisson (1)
-
Bonnie Rochman (1)
-
Bordeaux University Hospital (2)
-
borderline disease (1)
-
borderline resectable (1)
-
borderline resectable pancreatic (1)
-
Borealis-2 (1)
-
Boris Sepesi (1)
-
bortezomib (7)
-
bowel function (1)
-
brachytherapy (3)
-
brachytherapy implant (1)
-
Brad Kahl (3)
-
Bradley Monk (2)
-
Bradley Reames (1)
-
Bradley Zebrack (2)
-
BRAF (2)
-
BRAF mutation (2)
-
BRAF mutations (1)
-
BRAF V600 (2)
-
braf v600e (2)
-
BRAF-mutated tumors (1)
-
brain cancer (5)
-
brain metastases (11)
-
Branden May (1)
-
Brandon May (21)
-
Brandon Smaglo (1)
-
BRCA (8)
-
BRCA mutations (1)
-
BRCA status (1)
-
BRCA1 (4)
-
brca1/2 (1)
-
BRCA2 (4)
-
BRCA-mutated (1)
-
breast (1)
-
breast cancer (209)
-
Breast Cancer (53)
-
breast cancer diversity (1)
-
breast cancer genomics (1)
-
breast cancer in young women (2)
-
breast cancer incidence (1)
-
breast cancer mortality (1)
-
breast cancer prevention (1)
-
breast cancer screening (1)
-
breast cancer survivor (3)
-
breast cancer survivors (3)
-
breast conservation (1)
-
breast conserving surgery (2)
-
breast irradiation (1)
-
breast preserving surgery (1)
-
breast resection (1)
-
breast tumors (1)
-
breast-conserving surgery (1)
-
breast-conserving therapy (1)
-
Brenda Sandmaier (1)
-
Brendan F. Curley (1)
-
Brendan Guercio (2)
-
brentuximab vedotin (5)
-
bretrand coiffier (1)
-
Brett Wilson (1)
-
Bria Meyer (2)
-
Brian Bolwell (1)
-
Brian Chapin (1)
-
Brian Chen (1)
-
Brian Kavanagh (2)
-
Brian Rini (5)
-
Brian Weiss (1)
-
Brian Wolpin (1)
-
Bridgett Harr (2)
-
brigatinib (1)
-
Brigham and Women’s (1)
-
Brigham and Women’s Hospital (1)
-
Brigham and Women's Cancer Center (1)
-
Brigham and Women's Hospital (1)
-
BRIM8 trial (1)
-
Brinker Award lecture (1)
-
British Columbia Cancer Agency (4)
-
Britta Weigelt (1)
-
Brittany Bychkovsky (1)
-
brocade 3 (1)
-
bronchoscopy (1)
-
Bruce A. Chabner (1)
-
Bruce Cheson (6)
-
Bruce E. Johnson (1)
-
Bruce Haffty (1)
-
Bruce Johnson (3)
-
Bruce Levine (2)
-
Bruce Minsky (5)
-
Bruno Medeiros (1)
-
Brustzentrum der Universität Mün (1)
-
bruton's tyrosine kinase (1)
-
BTK (2)
-
BTK inhibitors (2)
-
buparlisib (1)
-
burden (1)
-
burden of care (1)
-
burden of treatment (1)
-
Burkitt lymphoma (2)
-
Burkitt’s lymphoma (1)
-
bursectomy (1)
-
business (5)
-
C.B. Allard (1)
-
cabazitaxel (4)
-
CABOSUN (1)
-
CABOSUN trial (1)
-
cabozantinib (9)
-
cachexia (5)
-
cachexia quality of life (1)
-
CAF (1)
-
calcium (1)
-
Caleb Dulaney (1)
-
CALGB 40502 (1)
-
CALGB 40503 (1)
-
CALGB 40601 (1)
-
CALGB 40601 Alliance (1)
-
calgb 40603 (1)
-
CALGB 40903 (1)
-
CALGB 80802 (1)
-
CALGB 80803 (1)
-
CALGB 89803 (2)
-
CALGB alliance trial (2)
-
CALGB trial (1)
-
CALGB/Alliance 50303 (1)
-
CALGB/Alliance 50604 (1)
-
CALM psychological intervention (1)
-
Calvin Dykstra (1)
-
Cameron Turtle (2)
-
cancer (60)
-
Cancer and Aging Research Group (1)
-
cancer biomarker (1)
-
cancer care (3)
-
cancer caregiving (1)
-
cancer centers (2)
-
Cancer Council Queensland (1)
-
cancer delirium (1)
-
cancer diagnosis (1)
-
cancer discoveries (1)
-
cancer drug development (1)
-
cancer experience (1)
-
cancer genetics (1)
-
Cancer Genome Atlas (1)
-
cancer imaging (1)
-
cancer in India (1)
-
cancer in South America (1)
-
cancer in the Middle East (1)
-
cancer incidence (2)
-
cancer management (2)
-
cancer metastases (1)
-
cancer mortality (3)
-
cancer of the unknown primary (1)
-
cancer outcomes (3)
-
cancer pain (8)
-
cancer pain management (1)
-
cancer prevention (2)
-
cancer recurrence (4)
-
cancer research (4)
-
Cancer Research UK (1)
-
Cancer Research UK Centre (1)
-
cancer risk (1)
-
cancer screening (6)
-
cancer staging (4)
-
cancer support services (1)
-
cancer surgery (1)
-
cancer survival (1)
-
cancer survivor (16)
-
cancer survivors (1)
-
cancer survivorship (4)
-
Cancer Survivorship Symposium (23)
-
cancer treatment (6)
-
Cancer Treatment Centers of Amer (2)
-
cancer treatment outcomes (1)
-
cancer vaccine (2)
-
cancer vaccines (1)
-
CancerCare (1)
-
CancerLinQ (4)
-
cancer-related pain (1)
-
cancer-specific survival (1)
-
candor trial (1)
-
capecitabine (15)
-
caplacizumab (1)
-
CAPTIVATE trial (1)
-
car t (1)
-
CAR T cell (1)
-
CAR T cell therapy (2)
-
CAR T cells (2)
-
CAR T-cell (3)
-
car t-cell therapy (6)
-
CAR T-cells (2)
-
CAR therapy (1)
-
Cara Glynn (1)
-
Carbone Cancer Center (2)
-
carboplatin (12)
-
carcinomatosis (1)
-
CARD trial (1)
-
cardiac effects (1)
-
cardiac radiation (1)
-
cardiac toxicity (1)
-
Cardiff University (1)
-
Cardinale Smith (1)
-
cardiotoxicity (2)
-
cardiovascular (1)
-
cardiovascular disease (3)
-
cardiovascular toxicities (1)
-
care coordination (1)
-
care disparities (1)
-
care plan (2)
-
care program (1)
-
caregiver (2)
-
caregivers (2)
-
Carey Anders (2)
-
carfilzomib (5)
-
Carina Storrs (1)
-
Carl Singerman (1)
-
CARLA CASULO (1)
-
Carlo Alfredo Clerici (1)
-
Carlos Arteaga (2)
-
Carlos Barrios (1)
-
Carlos Rene Valdez (1)
-
Carmea trial (2)
-
carmena (1)
-
Carol Goodrich (1)
-
Carol Kuehnert (1)
-
Carol Lee (1)
-
Carol Tietz (1)
-
Carol Veio (1)
-
CAROLINA TANNENBAUM-BARUCHI (1)
-
Carolina Urologic Research Center (1)
-
Carolinas Medical Center (1)
-
Caroline Helwick (2061)
-
Caroline Helwick and Alice Goodman (3)
-
Caroline Hopkins (3)
-
Caroline McNeil (69)
-
Caroline Robert (2)
-
Caroline Wellbery (1)
-
Carolyn Hendricks (1)
-
Carolyn Matthews (1)
-
Carolyn Presley (2)
-
Carolyn Runowicz (1)
-
Carrie Kreiswirth (1)
-
Carrie Snyder (1)
-
Carson Rolleri (4)
-
CAR-T (2)
-
CAR-T cells (1)
-
cas9 (1)
-
CASSINI (1)
-
castelman disease (1)
-
castleman disease collaborative network (1)
-
CASTOR trial (4)
-
castrate-resistant (2)
-
castration resistant (1)
-
castration-resistant (14)
-
castration-resistant prostate ca (2)
-
castration-sensitive (3)
-
Catherine C. Coombs (1)
-
Catherine Coombs and Anthony Mato (1)
-
Catherine Park (2)
-
Catherine Thieblemont (2)
-
Cathy Eng (2)
-
CATNON trial (1)
-
Catriona McNeil (3)
-
catumaxomab (1)
-
Caucasian (1)
-
cause-specific mortality (1)
-
CBT (1)
-
cc-486 (1)
-
CCF (2)
-
CCGA (1)
-
CCOG 1102 (1)
-
CCTG/AGITG napabucasin (1)
-
CD19 (1)
-
CD-19 (1)
-
CD19+ lymphoma (1)
-
CD-20 positive (1)
-
CD274 (1)
-
CD30 (2)
-
CD-30 (1)
-
CD38 (1)
-
cd79a (1)
-
CD81 cells (1)
-
CDK inhibitor (1)
-
CDK4 inhibitor (1)
-
CDK4/6 inhibitor (1)
-
CDK4/6 Inhibitors (1)
-
CDK46 (1)
-
CEA tumor marker (1)
-
Cedars-Sinai (6)
-
Cedars-Sinai Medical Center (3)
-
cediranib (1)
-
Ceilidh Eaton Russell (1)
-
celecoxib (1)
-
Celestia Higano (2)
-
CELESTIAL (2)
-
cell-free DNA (1)
-
cellular therapy (2)
-
cemiplimab (2)
-
Center for International Blood a (1)
-
central nervous system metastase (1)
-
Centre Antoine-Lacassagne (2)
-
Centre Eugene Marquis (2)
-
Centre Leon Berard (1)
-
Centre Léon Bérard (1)
-
Centre R Gauducheau (1)
-
Centre Régional de Lutte Contre (1)
-
CEO (1)
-
Cerdulatinib (1)
-
ceritinib (4)
-
cervical cancer (8)
-
Cesar A. Santa-Maria (2)
-
Cesar Santa-Maria (1)
-
cetuximab (10)
-
ch14.18/CHO (2)
-
CHAARTED trial (1)
-
Chadi Nabhan (1)
-
challenges in cancer care (1)
-
Chanan-Khan (1)
-
Chandrakanth Are (43)
-
Channing Paller (5)
-
Charity Oyedeji (1)
-
Charles Bennett (4)
-
Charles Blanke (1)
-
Charles Drake (1)
-
Charles Duvall (2)
-
charles e. geyer (2)
-
Charles E. Geyer Jr. (3)
-
Charles F. von Gunten (2)
-
Charles L. Bennett (5)
-
Charles Loprinzi (2)
-
Charles Rudin (1)
-
CHARLES RYAN (1)
-
Charles Schiffer (2)
-
Charles Simone (1)
-
Charles von Gunten (3)
-
charlo (1)
-
Charlotte Bath (701)
-
CHARU AGGARWAL (2)
-
Chase Doyle (510)
-
chasing my cure (1)
-
Chau Dang (2)
-
Checkmate (2)
-
CheckMate 025 (1)
-
CheckMate 032 (3)
-
CheckMate 039 (1)
-
CheckMate 067 (1)
-
CheckMate 141 (1)
-
CheckMate 142 (1)
-
CheckMate 214 (2)
-
CheckMate 214 trial (1)
-
checkmate 227 (1)
-
checkmate 238 (1)
-
CheckMate 238 trial (1)
-
CheckMate 275 (1)
-
checkmate 384 (1)
-
checkmate 650 (1)
-
CheckMate 67 (2)
-
CheckMate-032 (1)
-
CheckMate-142 (2)
-
checkpoint antibodies (2)
-
checkpoint blockade (3)
-
checkpoint inhibitor (4)
-
checkpoint inhibitors (5)
-
checkpoint kinase inhibitor (1)
-
chemobrain (1)
-
chemoendocrine (2)
-
chemoimmunotherapy (4)
-
chemoimmunotherapy, first-line therapy, follicular lymphoma, nccn hematologic malignancies, targeted biologics (1)
-
chemopreventative (2)
-
chemoradiation (6)
-
chemoradiotherapy (9)
-
chemoresistance (1)
-
chemotherapy (80)
-
chemotherapy duration (1)
-
chemotherapy errors (1)
-
chemotherapy naive (1)
-
chemotherapy toxicity (1)
-
chemotherapy-induced (1)
-
chemotherapy-induced peripheral (1)
-
chemotherapy-ineligible (1)
-
chemotherapy-naive (3)
-
chemotherapy-naïve (1)
-
Cheryl Ewing (1)
-
Cheryl Krafft (1)
-
chest infections (1)
-
chest wall radiation (1)
-
Chevalier Jackson (1)
-
CHHiP trial (2)
-
Chiara Magni (1)
-
Chijioke Nze (1)
-
childhood ALL (2)
-
childhood cancer (2)
-
childhood cancer survivor (2)
-
Childhood Cancer Survivor Study (1)
-
childhood cancer survivors (2)
-
children (1)
-
Children’s Oncology Group (1)
-
chimeric antigen receptor (5)
-
China (1)
-
Chinese U of Hong Kong (1)
-
Chinese University (1)
-
Chinese University of Hong Kong (5)
-
Chip Baldwin (1)
-
Chloe Atreya (2)
-
chlorambucil (2)
-
cholangiocarcinoma (2)
-
Choosing Wisely Campaign (1)
-
CHOP (2)
-
CHOP-R (1)
-
CHP (1)
-
CHRIS LABAKI (1)
-
Chris Leonardis (1)
-
Chris O'Brien Lifehouse (1)
-
Chris Parker (1)
-
Christian Blank (2)
-
Christian Carrie (2)
-
Christian Nelson (1)
-
Christian-Albrechts University K (2)
-
Christiane Querfeld (1)
-
Christiane Voit (1)
-
Christie NHS Foundation Trust (3)
-
Christina Best (1)
-
Christina Chu (2)
-
Christina S. Chu (1)
-
Christina Seluzicki (1)
-
Christine Berg (1)
-
Christine Boers-Doets (1)
-
Christoph Zielinski (2)
-
Christopher Allard (1)
-
Christopher Barker (1)
-
Christopher Buettner (1)
-
Christopher Campen (5)
-
Christopher Flowers (1)
-
CHRISTOPHER HOIMES (1)
-
Christopher Kelsey (1)
-
Christopher Logothetis (1)
-
Christopher Recklitis (4)
-
Christopher Rose (2)
-
Christopher Steer (1)
-
Christopher Sweeney (9)
-
Christopher Willett (1)
-
chronic disease (1)
-
chronic lymphocytic leukemia (21)
-
chronic morbidity (1)
-
chronic myeloid leukemia (8)
-
chronic myelomonocytic leukemia (1)
-
chronic pain (1)
-
chronic-phase CML (2)
-
Chung-Han Lee (1)
-
Ciara Freeman (1)
-
CIBMTR (1)
-
CIBOMA/GEICAM Trial (1)
-
Cicely Saunders (1)
-
Cincinnati Children's Hospital M (1)
-
Cindy Brown (1)
-
Cindy Chavez (1)
-
CINV (3)
-
CINV prevention (1)
-
CIPN (1)
-
circulating free DNA (2)
-
circulating tumor cells (6)
-
circulating tumor DNA (10)
-
cisplarin (1)
-
cisplatin (19)
-
cisplatin-based chemotherapy (2)
-
cisplatin-ineligible (2)
-
Città della Salute e della Scie (1)
-
City of Hope (19)
-
Clara Bloomfield (1)
-
claridhy trial (1)
-
classical Hodgkin lymphoma (1)
-
Claus Garbe (4)
-
Clayton B. Hess (1)
-
CLDN18.2 positive disease (2)
-
clear cell (2)
-
clear cell rcc (1)
-
clear cell renal cancer (1)
-
CLEOPATRA trial (1)
-
Cleveland Clinic (19)
-
Cliff Goodman (1)
-
Cliff Hudis (5)
-
clifford a. hudis (2)
-
Clifford Goodman (1)
-
Clifford Hudis (31)
-
clinical (1)
-
clinical benefit (1)
-
clinical cancer advances (1)
-
clinical decision-making (2)
-
clinical endpoint (1)
-
clinical management (1)
-
clinical outcomes (2)
-
clinical pathways (2)
-
clinical practice (1)
-
clinical research (1)
-
clinical resources (1)
-
clinical treatment score (1)
-
clinical trial (1)
-
clinical trial eligibility (2)
-
clinical trial screening (1)
-
clinical trials (12)
-
clinician-patient communication (1)
-
CLL (29)
-
clofarabine (1)
-
CME (1)
-
CML (10)
-
CMML (2)
-
CMS (2)
-
CNS cancer (1)
-
CNS cancers (1)
-
CNS Cancers (1)
-
CNS disease (1)
-
CNS involvement (1)
-
CNS metastases (1)
-
CNS prophylaxis (2)
-
CNS-penetrable (1)
-
cobimetinib (1)
-
cognition (1)
-
cognitive behavior therapy (1)
-
cognitive decline (1)
-
cognitive failure (1)
-
cognitive function (3)
-
Coiffier (1)
-
co-insurance (1)
-
Cold Spring Harbor Laboratory (1)
-
Colette Owens (1)
-
Colin Weekes (1)
-
colitis (2)
-
collaborative pain management (1)
-
collection kit (1)
-
COLLEEN M. FELTMATE (1)
-
Colleen Smith (1)
-
COLO-001 trial (1)
-
colon cancer (11)
-
colony-stimulating factors (1)
-
colopec trial (1)
-
colorectal (1)
-
colorectal cancer (36)
-
Colorectal Cancer (24)
-
colorectal cancer liver metastases (1)
-
colorectal cancer survivor (1)
-
Columbia University (2)
-
Columbia University Medical Cent (2)
-
Columbia University Medical Center (1)
-
COLUMBUS trial (1)
-
COMBI-AD (1)
-
combination immunotherapy (4)
-
combination therapies (3)
-
combination therapy (3)
-
combination treatments (1)
-
combined positive score (1)
-
Coming Soon (1)
-
Commission on Cancer (1)
-
communication barrier (1)
-
communication in oncology (2)
-
communication studies (1)
-
community (1)
-
community cancer center (1)
-
community oncology (7)
-
community practice (2)
-
community practices (1)
-
community setting (2)
-
community sites (1)
-
comorbidites (1)
-
comorbidities (3)
-
comorbidity score (1)
-
comorbitides (1)
-
compass trial (2)
-
completely resected (1)
-
complication rate (1)
-
comprehensive cancer centers (1)
-
computed tomography (1)
-
computer assistance (1)
-
computerized evaluation (1)
-
concurrent radiation (1)
-
Cone Health Cancer Center (1)
-
conformal radiation (1)
-
Conquer Cancer Foundation (2)
-
Conquer Fear (1)
-
consolidation chemotherapy (1)
-
consolidation radiotherapy (1)
-
consolidative radiotherapy (1)
-
consolidative therapy (1)
-
continued care (1)
-
continuing medical education (1)
-
contralateral breast cancer (1)
-
conventional (1)
-
conventional fractionation radio (1)
-
conventionally fractionated (2)
-
conventionally fractionated radi (1)
-
conversation guides (1)
-
co-occurring mutations (1)
-
cooling cap (1)
-
COPD (1)
-
Copenhagen University Hospital (4)
-
coping mechanisms (1)
-
Cora N. Sternberg (1)
-
Cora Sternberg (6)
-
CORAL trial (1)
-
core biopsy (1)
-
Corey Cutler (1)
-
Cornelis van de Velde (1)
-
coronary calcification (1)
-
coronary heart disease (1)
-
coronavirus (34)
-
coronavirus italy (4)
-
coronavirus waves (1)
-
correlative studies (1)
-
cosmesis (1)
-
cosmetic outcome (1)
-
cost (1)
-
cost analysis (2)
-
cost benefit (1)
-
cost curve (1)
-
cost of care (21)
-
Cost of Care (2)
-
cost reductions (1)
-
cost savings (1)
-
cost-effectiveness (3)
-
cough (2)
-
cough mechanisms (1)
-
counseling (1)
-
course of therapy (1)
-
course of treatment (1)
-
Courtney Davis (1)
-
COVID-19 (22)
-
COVID-19 (21)
-
covid-19 research (1)
-
COX-2 over expression (1)
-
cps (1)
-
CPX-351 (1)
-
CR30 (1)
-
Craig Alguire (1)
-
Craig Earle (1)
-
Craig Moskowitz (3)
-
Craig Pollack (2)
-
cranial radiotherapy (1)
-
CREATE-X clinical trial (1)
-
Creighton University (1)
-
CRISPR (1)
-
Cristina Meazza (1)
-
criteria expansion (1)
-
CRITICS trial (1)
-
crizotinib (9)
-
Cross Cancer Institute (1)
-
crpc (3)
-
Crystal Denlinger (2)
-
CSF (1)
-
CT follow-up (1)
-
CT scan (5)
-
CT screening (1)
-
CT019 (1)
-
cT3 rectal cancer (1)
-
cT4 rectal cancer (1)
-
CTCL (1)
-
CTCs (5)
-
ctDNA (7)
-
ctla-4 (1)
-
ctnda (1)
-
cts5 (1)
-
cultural barriers (1)
-
cultural differences (1)
-
CUMC (2)
-
curable cancer (1)
-
curative surgery (1)
-
cutaneous melanoma (1)
-
cutaneous SCC (1)
-
cutaneous squamous cell carcinom (2)
-
cutaneous T cell lymphoma (1)
-
cutoff (1)
-
cutting-edge treatment (2)
-
CXCR4 inhibitor (1)
-
cyclophosphamide (7)
-
cyclosporine (1)
-
Cynthia Hayes (1)
-
Cynthia Sears (1)
-
cystectomy (2)
-
cytarabine (2)
-
cytopenias (1)
-
D. Ross Camidge (1)
-
D538G mutation (1)
-
dabrafenib (6)
-
dabrafenib monotherapy (1)
-
dacarbazine (2)
-
dacomitinib (2)
-
DA-EPOCH-R (2)
-
DA-EPOCH-R trial (1)
-
Dale Maloney (1)
-
dalteparin (1)
-
Damien Hansra (3)
-
Dan Labriola (1)
-
Dan Longo (2)
-
Dan Shapiro (1)
-
Dan Zandberg (1)
-
Dana Barnea (2)
-
Dana Farber (3)
-
Dana Farber Cancer Insitute (3)
-
Dana Farber Cancer Institute (1)
-
Dana Stewart (1)
-
Dana-Farber (27)
-
Dana-Farber Cancer Institute (61)
-
Dana-Farber Clinical Pathways (1)
-
Dana-Farber Institute (1)
-
Danelle James (1)
-
Daniel A. Goldstein (1)
-
DANIEL ANAYA (1)
-
Daniel Barocas (1)
-
Daniel Cahill (2)
-
Daniel Chang (1)
-
Daniel DeAngelo (1)
-
Daniel den Hoed Cancer Center (1)
-
Daniel Epner (4)
-
Daniel F. Hayes (6)
-
Daniel Garza (1)
-
Daniel Geynisman (1)
-
Daniel Goldstein (1)
-
Daniel Gomez (1)
-
Daniel Haller (3)
-
Daniel Hamstra (1)
-
Daniel Hayes (4)
-
Daniel Heng (1)
-
Daniel J. Lenihan (1)
-
Daniel Kopans (2)
-
Daniel Lin (1)
-
Daniel Morgensztern (1)
-
Daniel Petrylak (1)
-
Daniel Rayson (4)
-
Daniel Richardson (1)
-
Daniel Spratt (1)
-
Daniel Vilarim Araujo (1)
-
Daniel Vorobiof (4)
-
Daniel W. Lin (1)
-
Danielle Ripley Burgess (1)
-
DANIELLE THOLEY (1)
-
danorubicin (1)
-
daratumumab (14)
-
Darcy Lewis (1)
-
Dario Altieri (1)
-
Dario Trapani (1)
-
darolutamide (2)
-
Darrell Skaggs (1)
-
Dartmouth-Hitchock (1)
-
dasatinib (1)
-
Dasha Shkurpela (1)
-
data set (1)
-
DATA trial (1)
-
daunorubicin (2)
-
DAVID BRAUN (1)
-
David Dearnaley (2)
-
David Ettinger (2)
-
David Fredricks (1)
-
David G. Pfister (1)
-
David Geffen School of Medicine (1)
-
David Gerber (2)
-
David Gershenson (1)
-
David Gustafson (1)
-
David Henry (5)
-
David Hyman (1)
-
David Hysong (1)
-
David Ilson (3)
-
David Irwin (1)
-
David J. Kopsky (1)
-
David Kim (1)
-
David Kissane (3)
-
David Korones (1)
-
David M. O'Malley (1)
-
David Maloney (2)
-
David McDermott (1)
-
David Mitchell (1)
-
David Nathan (1)
-
David Neises (1)
-
David O’Malley (1)
-
David Porter (3)
-
David Posner (1)
-
David Quinn (1)
-
David Ryan (1)
-
David Steensma (3)
-
David Straus (2)
-
David Tuveson (1)
-
David Victorson (1)
-
David Wellenstein (1)
-
David Williams (1)
-
David Wise (1)
-
David Ziegler (1)
-
Dawn Hershman (4)
-
Dawn Lemanne (2)
-
Dawn Yates (1)
-
DBCG778 (1)
-
DCIS (6)
-
Dean Bajorin (3)
-
Deanna King (1)
-
death (1)
-
Death With Dignity Act (1)
-
death with dignity laws (1)
-
Debbie Davis (1)
-
Debbie Wasserman Schultz (1)
-
debilitating grief (1)
-
Deborah Doroshow (1)
-
Deborah Marshall (1)
-
Debra Bowler (1)
-
Debu Tripathy (1)
-
debulking surgery (2)
-
Decipher prostate cancer classif (1)
-
decision making (1)
-
decision support (1)
-
decision-making (1)
-
decitabine (1)
-
DECOG trial (2)
-
Dee Sparacio (1)
-
deep molecular response (1)
-
deep remission (1)
-
Deepa Wadhwa (1)
-
de-escalating therapy (1)
-
Defense Health Agency (1)
-
deintensification (1)
-
deintensified therapy (1)
-
delay in care (1)
-
delirium (1)
-
delivery of care (1)
-
denintuzumab mafodotin (1)
-
Denise Lee (1)
-
Denise Leprine (1)
-
DENISE MILLSTINE (1)
-
Denise Yardley (1)
-
denosumab (3)
-
depression (9)
-
Derek Jonker (1)
-
Derek Raghavan (15)
-
dermatologic toxicities (1)
-
Derriford Hospital (1)
-
despair (1)
-
DESTINY study (1)
-
developing world (1)
-
Devorah Aschendorf (1)
-
dexamethasone (14)
-
dfs (1)
-
diagnosis (2)
-
diagnostic criteria (1)
-
diagnostics (2)
-
Diana Byrnes (1)
-
Diana Eccles (1)
-
Diana Heller (1)
-
Diana Jeffery (1)
-
Diane Portman (2)
-
Dianne Spillman (1)
-
diarrhea (2)
-
Diego Davis-Olegário (1)
-
diet (2)
-
dietary intervention (1)
-
Dieter Hoelzer (1)
-
diffuse large B cell (1)
-
diffuse large B cell lymphoma (11)
-
diffuse large B-cell lymphoma (15)
-
diffuse midline glioma (1)
-
dignicap (1)
-
Dimas Padilla (1)
-
direct oral anticoagulants (1)
-
direct-to-patient (1)
-
discontinuing therapy (1)
-
discontinuing treatment (1)
-
disease burden (1)
-
disease control (1)
-
disease heterogeneity (1)
-
disease imaging (1)
-
disease management (1)
-
disease outcomes (1)
-
disease progression (8)
-
disease recurrence (4)
-
disease staging (1)
-
disease survival (1)
-
disease-free survival (5)
-
disparities (1)
-
distant cancer recurrence (1)
-
distant disease (1)
-
distant disease–free survival (1)
-
distant lesions (1)
-
distant metastasis-free survival (1)
-
distress (7)
-
distress screening (2)
-
distress thermometer (2)
-
diversity (1)
-
DLBCL (23)
-
DLL-3 (3)
-
DNA alteration (1)
-
DNA damage (1)
-
DNA damage repair deficiencies (1)
-
DNA damage-repair pathway (1)
-
DNA mistmatch repair (1)
-
DNA repair (2)
-
DOACs (2)
-
docetaxel (31)
-
docetaxel monotherapy (1)
-
doctor-patient behavior (1)
-
Domenica Lorusso (1)
-
Don Stranathan (1)
-
Donald Abrams (1)
-
Donald Garrity (1)
-
Donald I. Abrams (1)
-
Donald L. Trump (1)
-
Dong Wook Shin (1)
-
Donna Bell (1)
-
Donna Chen (1)
-
Donna Fernandez (1)
-
Donna Piunt (1)
-
Dori Klemanski (1)
-
Dorothy Lombe (2)
-
Dorothy Turner (1)
-
dosage (2)
-
dose (1)
-
dose decrease (1)
-
dose de-escalation (1)
-
dose density (1)
-
dose escalation (3)
-
dose fractionation (1)
-
dose intensity (1)
-
dose lowering (1)
-
dose reduction (1)
-
dose response (1)
-
dose-dense chemotherapy (1)
-
double-expressor lymphoma (1)
-
double-hit lymphoma (1)
-
doublet (1)
-
Douglas Arthur (1)
-
Douglas B. Johnson (2)
-
Douglas Lowy (1)
-
Douglas Wood (3)
-
doxorubicin (8)
-
driver mutations (1)
-
droplet digital PCR (1)
-
drug approvals (1)
-
drug combination (1)
-
drug conjugates (1)
-
drug costs (1)
-
drug development (3)
-
drug disparities (1)
-
drug indications (1)
-
dry mouth (1)
-
ductal carcinoma in situ (5)
-
Duke Cancer Center (3)
-
Duke Cancer Insitute (1)
-
Duke Cancer Institute (4)
-
Duke Medical Center (1)
-
Duke University (7)
-
duloxetine (1)
-
Dung Le (6)
-
duration of treatment (1)
-
durvalumab (8)
-
duvelisib (1)
-
E. David Crawford (4)
-
E. George Elias (3)
-
E7208 trial (1)
-
early breast cancer (10)
-
early cancer detection (1)
-
early CDT (1)
-
early detection (5)
-
early distant recurrence (1)
-
early menopause (1)
-
early palliative care (3)
-
early referral (1)
-
early relapsing (1)
-
early salvage radiotherapy (1)
-
early stage (2)
-
early stage breast cancer (2)
-
early stage lung cancer (1)
-
early toxicity (1)
-
early-phase trials (1)
-
early-stage (3)
-
early-stage breast cancer (7)
-
early-stage cancer (1)
-
early-stage diagnosis (1)
-
early-stage disease (1)
-
ease of use (1)
-
Eastern Europe (1)
-
EBCTCG (1)
-
ebrt (1)
-
ECC 2015 (29)
-
ECCO (1)
-
ECCO 2015 (2)
-
ECHELON-1 trial (1)
-
ECHELON-2 (1)
-
ECOG (1)
-
ECOG 1505 (1)
-
ECOG ACRIN 2511 (1)
-
ECOG-ACRIN (1)
-
ecog-acrin 5508 (1)
-
Ed Giampietro (1)
-
edith a. perez (1)
-
Edith Perez (4)
-
Edmond Ang (1)
-
Edoardo Francini (1)
-
Eduardo Bruera (6)
-
Eduardo Cazap (4)
-
Eduardo L. Cazap (1)
-
Edvardas Kaminskas (1)
-
Edward Garon (1)
-
Edward George (1)
-
Edward Kim (1)
-
Edward Romond (1)
-
efficacy (3)
-
EFGR mutation (1)
-
EGFR (7)
-
EGFR inhibitor (1)
-
EGFR mutation (8)
-
EGFR positive (1)
-
EGFR resistance (1)
-
EGFR signaling (1)
-
EGFR T709M (1)
-
egfr tki (1)
-
EGFR+ NSCLC (1)
-
EHA25 Virtual (10)
-
Eileen Danaher Hacker (1)
-
Eileen M. O'Reilly (1)
-
Eileen O'Reilly (2)
-
elderly (1)
-
elderly patient (2)
-
elderly patients (1)
-
e-learning (1)
-
elective nodal irradiation (1)
-
Electra Paskett (4)
-
electronic medical records (1)
-
electronic support (1)
-
electronic symptom monitoring (1)
-
electronic tools (1)
-
electroporation (1)
-
Elena Elimova (1)
-
Eleni Efstathiou (1)
-
elevate tn (1)
-
elevated PSA (1)
-
Eli Lilly (1)
-
Elias Jabbour (1)
-
Elias Zahalka (1)
-
Eliezer Robinson (3)
-
Eliezer Van Allen (2)
-
Elihu Estey (2)
-
ELIZA A. HAWKES (1)
-
Elizabeth A. Comen (1)
-
Elizabeth Gerstner (1)
-
Elizabeth Kessler (1)
-
Elizabeth L. Travis (1)
-
Elizabeth Mittendorf (1)
-
Elizabeth Plimack (1)
-
Elizabeth Reed (1)
-
Elizabeth Shpall (1)
-
Elizabeth Simmons (1)
-
Ella Muller (1)
-
Ellen Miller-Sonet (1)
-
Ellen Sigal (4)
-
Ellin Berman (1)
-
ELOQUENT-2 (1)
-
elotozumab (1)
-
elotuzumab (3)
-
embryo (1)
-
emergency department (2)
-
emergency department costs (1)
-
emergency department use (1)
-
emergency surgery (1)
-
emerging therapies (1)
-
emetic (1)
-
emetogenic (2)
-
emetogenic chemotherapy (1)
-
Emil J. Freireich (3)
-
Emily A. Kuhl (3)
-
Emily Castellanos (1)
-
Emily Dumler (1)
-
Emily Haozous (1)
-
Emily Kuhl (21)
-
Emily Tonorezos (2)
-
Emily Zurbuchen (1)
-
Emma Hall (1)
-
Emory (1)
-
Emory Kinship Cancer Institute (1)
-
Emory University (11)
-
Emory University School of Medic (4)
-
emphysema (2)
-
EMR (1)
-
EMRs (1)
-
ENABLE model (1)
-
encequidar (1)
-
encorafenib (2)
-
end of life (5)
-
endocrine resistance (1)
-
endocrine side effects (1)
-
endocrine therapy (16)
-
endocrine therapy-resistant (1)
-
endocrine treatment (1)
-
endocrine-based therapy (1)
-
end-of-life (3)
-
end-of-life care (8)
-
end-of-life issues (1)
-
endometrial cancer (4)
-
EndoPredict (1)
-
endoscopy (1)
-
endothelial function (2)
-
enestop (1)
-
enfortumab vedotin (1)
-
ENGOT-OV16 NOVA (1)
-
ENGOT-OV16/NOVA (1)
-
enhanced quality (1)
-
Enrica Marchi (1)
-
Enrique Soto Perez-de-Celis (2)
-
enzaludamide (3)
-
enzalutamide (14)
-
EnzaMet (1)
-
enzamet trial (1)
-
EnzaRad (1)
-
EORTC (2)
-
EORTC 18071 (1)
-
EORTC 90101 CREATE (1)
-
epacadostat (1)
-
ePAL (1)
-
ependymoma (1)
-
epidemiology (1)
-
epidemiology in younger patients (1)
-
epirubicin (2)
-
epithelial ovarian cancer (5)
-
EPOCH-R (1)
-
eprirubicin (2)
-
equality (1)
-
ER visits (1)
-
ER+ (1)
-
ER+ breast cancer (5)
-
ER+ metastatic (1)
-
ER+/HER2– (1)
-
Erasmus University (1)
-
erectile function (1)
-
eribulin (1)
-
Eric Bouffet (1)
-
Eric Francois (4)
-
Eric Genden (1)
-
Eric Jonasch (3)
-
Eric Lax (1)
-
Eric Lim (2)
-
Eric Lis (1)
-
Eric M. Horwitz (1)
-
Eric Pujade-Lauraine (1)
-
Eric Roeland (10)
-
Eric S. Zhou (1)
-
Eric Van Cutsem (2)
-
Eric Winer (4)
-
Eric Wisotzky (1)
-
Erica Kaye (1)
-
Erica Mayer (2)
-
Erich Sturgis (1)
-
Erika Hamilton (1)
-
Erika Ramsdale (1)
-
Erin Hahn (2)
-
Erin Van Blarigan (1)
-
erlotinib (6)
-
Ernest Greenberg (2)
-
Ernest Hawk (3)
-
ER-positive (5)
-
ER-positive breast cancer (1)
-
ER-positive metastatic breast ca (1)
-
ESMO (28)
-
ESMO 16 (3)
-
ESMO 2015 (1)
-
ESMO 2016 (42)
-
ESMO 2017 (23)
-
ESMO 2018 (21)
-
esmo 2020 (20)
-
esophageal adenocarcinoma (1)
-
esophageal cancer (12)
-
esophageal carcinoma (1)
-
esophageal squamous cell carcino (1)
-
esophagectomy (2)
-
ESPAC-4 trial (1)
-
ESR1 mutation (1)
-
estrogen (1)
-
estrogen deprivation (1)
-
estrogen receptor (2)
-
estrogen receptor 1 (1)
-
estrogen receptor positive (3)
-
estrogen receptor-positive (9)
-
estrogen-receptor positive (2)
-
Ethan Basch (4)
-
Ethan Dmitrovsky (2)
-
ethics (2)
-
ethnicity (1)
-
Etienne Brain (1)
-
etoposide (2)
-
Eugene Tombler (6)
-
Eugenie Spiguel (4)
-
Eurocare (1)
-
Europe (1)
-
European Cancer Congress 2015 (1)
-
European Institute of Oncology (1)
-
European Medicines Agency (1)
-
European Myeloma Network Trial (2)
-
European Union (1)
-
euthanasia (1)
-
Eva Joseph (1)
-
Eva Pendleton (1)
-
Evan Lipson (2)
-
Evangelia Razis (1)
-
Everett Vokes (4)
-
everolimus (12)
-
evidence (1)
-
evidence-based (1)
-
Example (1)
-
exemestane (4)
-
exercise (4)
-
exercise intervention (1)
-
exercise oncology (1)
-
exome sequencing (1)
-
exon 14 (1)
-
exon 18 (1)
-
exon 19 (1)
-
exon 20 (1)
-
exon 21 (1)
-
exon skipping (1)
-
expanded access (2)
-
experimental treatment (1)
-
ExteNET trial (1)
-
extensive-stage sclc (1)
-
external beam (1)
-
external beam radiation (1)
-
external-beam radiation (1)
-
extrahepatic disease (2)
-
extreme hypofractionation (1)
-
EZH2 (1)
-
Ezra Cohen (1)
-
F. Owen Hoffman (5)
-
Fabiana Passoni (1)
-
Fabrice Barlesi (2)
-
Fabrice Denis (2)
-
facility volume (1)
-
FACP (1)
-
FACS trial (1)
-
FADI G. HADDAD (1)
-
FADILA KOUHEN (1)
-
Fadlo Khuri (1)
-
FALCON trial (1)
-
fallopian tube cancer (3)
-
familial cancer risk (1)
-
families (1)
-
family and patient outcomes (1)
-
family caregivers (1)
-
family centered care (1)
-
family history (1)
-
Farhad Ravandi (9)
-
FASCO (2)
-
FASCO; CLIFFORD A. HUDIS (1)
-
FAST trial (3)
-
fat (1)
-
fatigue (7)
-
fatigue score (1)
-
FATIMA REZZOUG (1)
-
Fatima Rizvi (1)
-
FC Rad Onc (SA) (1)
-
FCR (1)
-
FCS (SA) (1)
-
Fc-receptor polymorphism (2)
-
FDA (5)
-
FDA approval (1)
-
FDA approvals (1)
-
fda oncology center of excellence (1)
-
fear of recurrence (2)
-
fears (1)
-
feasibility (1)
-
febrile neutropenia (1)
-
FEC 100 (1)
-
federal government (2)
-
federal law (1)
-
Federico Cappuzzo (2)
-
female leadership (1)
-
female patients (1)
-
female survivors (1)
-
fergi trial (1)
-
FERGIE trial (1)
-
Fernando Diaz (1)
-
fertility (2)
-
fertility preservation (3)
-
fertility-sparing surgery (1)
-
fertility-sparing treatment (1)
-
fetal development (1)
-
FGFR (2)
-
FGFR inhibitor (1)
-
FGFR3 (1)
-
fibrosis (1)
-
Filippo Spreafico (1)
-
financial burden (1)
-
financial guidance (1)
-
financial intervention (1)
-
financial toxicities (1)
-
financial toxicity (3)
-
Fiona Damstra (1)
-
fire-3 trial (1)
-
first complete remission (1)
-
first study (1)
-
FIRSTANA (1)
-
first-line chemotherapy (1)
-
first-line hormone therapy (1)
-
first-line therapy (11)
-
first-line treatment (4)
-
FISH (1)
-
FISH data (1)
-
fitness (1)
-
fixed duration (1)
-
FLASH (1)
-
FLASH study (1)
-
Flatiron Health (1)
-
FLAURA (1)
-
flaura trial (1)
-
FLORIAN LORDICK (1)
-
Florida International University (1)
-
FLOT4-AIO trial (1)
-
FLT3 (2)
-
FLT3-ITD (1)
-
fludarabine (3)
-
fluoropyrimidine (2)
-
fluorouracil (5)
-
fnf-004 trial (1)
-
focus group (1)
-
FOLFIRI (1)
-
FOLFIRI-bevacizumab (2)
-
FOLFIRINOX (3)
-
FOLFOX (2)
-
folfoxiri (1)
-
follicular lymphoma (18)
-
follow-up care (1)
-
follow-up scans (1)
-
Forte trial (2)
-
FORWARD II (1)
-
fosaprepitant (2)
-
Fox Chase (6)
-
Fox Chase Cancer Center (7)
-
fractionation (3)
-
fractionation schedule (1)
-
frailty (1)
-
Fran Visco (1)
-
Francis Crick Institute (3)
-
Francis Lévi (1)
-
Francis Paul Worden (2)
-
Francis S. Collins (1)
-
Francisco J. Esteva (1)
-
Franck Morschhauser (1)
-
Franco Cavalli (1)
-
Franco Muggia (2)
-
Frank Sierawski (1)
-
Fred Hirsch (9)
-
Fred Hutch (2)
-
Fred Hutch Cancer Center (2)
-
Fred Hutchinson (5)
-
Fred Hutchinson Cancer Center (2)
-
Fred Hutchinson Cancer Research (1)
-
Fred Hutchinson Cancer Research Center (2)
-
Fred Huthinson (1)
-
Fred R. Hirsch (1)
-
Fred Saad (6)
-
Frederic Amant (2)
-
Frederic Grannis (1)
-
Frederic Ivan Leong Ting (1)
-
Frederick Appelbaum (3)
-
Frederick Behm (1)
-
Fredrick B. Hagemeister (1)
-
freedom from distant recurrence (1)
-
French FILO Group (1)
-
Fritz Schröder (2)
-
front-line treatment (1)
-
fulvestrant (12)
-
Fumiko Chino (1)
-
function ability (1)
-
futile care (1)
-
futile treatment (1)
-
G.S. Raju (1)
-
Gabriel Hortobagyi (2)
-
gabriel lopez (1)
-
Gabriele Roden (1)
-
Gabrielle Rocque (1)
-
GADOLIN (3)
-
Gail Flores (6)
-
GALLIUM trial (1)
-
gamma-1 study (1)
-
Ganesh Shankar (1)
-
gap in access (1)
-
GARTH STROHBEHN (1)
-
Gary Deng (9)
-
Gary H. Lyman (3)
-
Gary Onik (1)
-
Gary Rodin (1)
-
Gary Steele (1)
-
Gary Whitman (1)
-
Gary Winkel (1)
-
gastrectomy (1)
-
gastric adenocarcinoma (3)
-
gastric cancer (16)
-
Gastric Cancer (1)
-
gastric junction adenocarcinoma (1)
-
gastric junction cancer (1)
-
gastroesophageal adenocarcinoma (3)
-
gastroesophageal cancer (2)
-
Gastroesophageal Cancer (9)
-
gastroesophageal junction (1)
-
gastroesophageal junction adenoc (2)
-
gastroesophageal junction cancer (2)
-
gastrointestinal cancer (20)
-
Gastrointestinal Cancer (11)
-
gastrointestinal cancers (1)
-
Gastrointestinal Cancers Symposi (15)
-
gastrointestinal side effects (1)
-
gastrointestinal tract (1)
-
Gautam Mehta (1)
-
gBRCA mutation (1)
-
gc4419 (1)
-
G-CSF (1)
-
gefitnib (2)
-
geftinib (3)
-
GEJ adenocarcinoma (1)
-
gej cancer (3)
-
gemcitabine (18)
-
Gemelli University Hospital (1)
-
GEMOX (1)
-
GEN503 clinical trial (1)
-
gender (1)
-
gene alterations (1)
-
gene biomarkers (1)
-
Gene Bishop (1)
-
gene expression (3)
-
gene expression profiling (1)
-
gene recurrence score (2)
-
gene signature (1)
-
gene therapy (1)
-
gene-expression model (1)
-
generic drugs (1)
-
genetic alterations (1)
-
genetic information (1)
-
genetic mutation (1)
-
genetic mutations (2)
-
genetic phenotype (1)
-
genetic predisposition (1)
-
genetic sequencing (2)
-
genetic testing (3)
-
genetic variants (1)
-
genetics (12)
-
genitourinary cancer (17)
-
Genitourinary Cancers Symposium (35)
-
genitourinary oncology (1)
-
genome-wide sequencing (1)
-
genomic (1)
-
genomic alterations (2)
-
genomic analysis (2)
-
genomic characterization (1)
-
genomic data (1)
-
Genomic Health (1)
-
genomic profiling (2)
-
genomic risk (1)
-
genomic screening (1)
-
genomic sequencing (3)
-
genomic studies (1)
-
genomic test (1)
-
genomic testing (2)
-
genomic tests (1)
-
genomic therapy (1)
-
genomics (11)
-
Genomics/Genetics (7)
-
genotyping (1)
-
Geoffrey I. Shapiro (1)
-
Geoffrey Ku (1)
-
Geoffrey R. Oxnard (2)
-
George Bosl (1)
-
George Canellos (2)
-
George Sledge (2)
-
George Somlo (1)
-
George Washington University (2)
-
Georgetown (1)
-
Georgetown University (8)
-
Georgia Cancer Center (1)
-
GeparNuevo (1)
-
GeparSixto (1)
-
Geraldine Carroll (5)
-
Gerard Morton (1)
-
Gerdes (1)
-
Gerhardt Attard (1)
-
geriatric assessment (1)
-
geriatric assessments (1)
-
geriatric oncology (13)
-
Geriatric Oncology (2)
-
geriatric patients (2)
-
geriatric survivorship (1)
-
geriatrician (1)
-
geriatrics (1)
-
germ cell tumor (2)
-
German Breast Group (4)
-
germline BRCA mutation (1)
-
germline BRCA ovarian cancer (1)
-
germline mutation (3)
-
germline testing (1)
-
GETUG-AFU 16 (1)
-
Gevorg Tamamyan (1)
-
Ghassan Abou-Alfa (1)
-
GI cancer (3)
-
gi cancers symposium (26)
-
GI Cancers Symposium 2017 (18)
-
Gideon Blumenthal (2)
-
Gideon Michael Blumenthal (1)
-
Gilbert Lawrence (3)
-
Gilberto Lopes (3)
-
Gilead 115 (1)
-
gilteritinib (1)
-
Gini Fleming (1)
-
Giorgio Scagliotti (3)
-
Giuseppe Del Priore (1)
-
glasdegib (1)
-
Gleason score (1)
-
glioblastoma (2)
-
glioma (1)
-
global access (1)
-
global access to drugs (1)
-
global cancer burden (1)
-
global cancer care (3)
-
Global Cancer Care (2)
-
global cancer disparities (1)
-
global health (1)
-
global health care (1)
-
global health costs (1)
-
global oncology (2)
-
global qol (1)
-
global standards (1)
-
glottic cancer (1)
-
glycan (1)
-
glycochip (1)
-
glycomics (1)
-
gm-csf (1)
-
GOLD trial (1)
-
gonadotropin-releasing hormone a (1)
-
Gopal Gupta (1)
-
Gordon Schiff (1)
-
goserelin (1)
-
Gouri Shankar Bhattacharyya (1)
-
government healthcare (1)
-
Govind Persad (12)
-
GOYA trial (1)
-
Graall-R 2005 study (1)
-
Grace Wang (1)
-
grade (1)
-
grading tumors (1)
-
graft vs host disease (1)
-
graft-versus-host-disease (1)
-
graft-vs-host-disease (1)
-
Graham A. Colditz (2)
-
Graham Watson (1)
-
Grant Achatz (1)
-
Grant R. Williams (1)
-
gray zone lymphoma (2)
-
grbca (1)
-
Greg Judy (1)
-
Gregory Armstrong (4)
-
Gregory Bociek (1)
-
Gregory H. Jones (1)
-
Gregory Otterson (1)
-
Greta Stifel (1)
-
grey zone lymphoma (1)
-
gross total resection (1)
-
gu cancers symposium (16)
-
GU Cancers Symposium 2017 (21)
-
gu cancers symposium, 5FU, mitomycin, chemotherapy, radiation therapy, MIBC, muscle-invasive bladder cancer (1)
-
gu cancers symposium, cost of care, abiraterone, ADT, androgen-deprivation therapy, qol, survival, stampede trial (1)
-
gu cancers symposium, crpc, immunotherapy, tki, monoclonal antibody (1)
-
gu cancers symposium, doublet, triplet, RCC, kidney cancer, renal cell carcinoma, immunotherapy (1)
-
GU Symposium 2016 (18)
-
guadecitabine (1)
-
guidance statement (1)
-
guideline (1)
-
guidelines (6)
-
Guido Marcucci (1)
-
Guneet Walla (1)
-
Gunter von Minckwitz (5)
-
Gurpreet Rooprai (1)
-
Guru Sonpavde (1)
-
Gustave Roussy (11)
-
Guy’s and St. Thomas’ Hospital (1)
-
GVHD (3)
-
Gwendolyn Quinn (1)
-
gynecologic cancer (3)
-
gynecologic cancers (6)
-
Gynecologic Cancers (22)
-
H. Jack West (1)
-
H. Lee Moffitt Cancer Center (7)
-
h3b-8800 (1)
-
HAGAR ELGHAZAWY (1)
-
Hagop Kantarjian (24)
-
HAGOP M. KANTARJIAN (1)
-
hair loss (2)
-
hairy cell leukemia (1)
-
Haiti (1)
-
halting treatment (1)
-
Hamilton Health Sciences (1)
-
Hamza Hashmi (2)
-
handgrip test (1)
-
Hannah Dzimitrowicz (1)
-
Hannah Stewart (9)
-
Hans Gerdes (1)
-
Hans Wildiers (2)
-
Hans-Joerg Hammers (2)
-
haploidentical transplantation (1)
-
Harefield Hospital (1)
-
Harold Burstein (8)
-
Harold J. Burstein MD (1)
-
Harriet Gross (1)
-
Harry Bear (3)
-
harry d. bear (2)
-
Harry Erba (1)
-
Harvard Medical School (5)
-
Harvey J. Cohen (1)
-
Hassan Errihani (2)
-
HAYLEY ARCENEAUX (1)
-
HCC (6)
-
head and neck (1)
-
head and neck cancer (21)
-
Head and Neck Cancer (8)
-
head and neck cancers symposium (9)
-
head and neck melanoma (2)
-
head and neck squamous cell carcinoma (1)
-
head and neck symposium (1)
-
health care delivery research (1)
-
health care disparities (6)
-
health care provider (1)
-
health care utilization (1)
-
health disparities (2)
-
health justice (3)
-
health outcomes (1)
-
health system (1)
-
health technology (1)
-
health-care (5)
-
health-care application (1)
-
healthcare costs (1)
-
health-care costs (1)
-
healthcare delivery (1)
-
health-care delivery (1)
-
health-care policy (2)
-
Health-Care Policy (2)
-
healthcare system (1)
-
health-care technology (1)
-
heart disease (2)
-
heart dose (1)
-
Heather Greenlee (1)
-
HEATHER McARTHUR (1)
-
Heather Sook Han (1)
-
Heather Thompson Buum (1)
-
Heather Wakelee (4)
-
hedgehog pathway inhibitor (1)
-
Heiddis Valdimarsdottir (1)
-
Heidi Klepin (1)
-
Heikki Joensuu (1)
-
Heinz-Josef Lenz (6)
-
Helen Ma (1)
-
Helen MacKay (2)
-
Helper (1)
-
hematologic (1)
-
hematologic malignancies (7)
-
Hematologic Malignancies (5)
-
hematologic malignancy (3)
-
hematology (16)
-
hematopoietic cell transplantati (1)
-
Heniz-Josef Lenz (1)
-
Henry Ford Cancer Center (1)
-
Henry Ford Health (1)
-
Henry Lynch (1)
-
heparin-induced thrombocytopenia (1)
-
hepatobiliary cancer (3)
-
Hepatobiliary Cancer (9)
-
hepatocellular carcinoma (18)
-
her2 (1)
-
HER2- (2)
-
HER2 blockade (2)
-
HER2- breast cancer (3)
-
her2 low (1)
-
her2 mutations (1)
-
HER2 negative (3)
-
HER-2 negative (1)
-
HER2 positive (3)
-
HER2 status (1)
-
her2 tki (1)
-
HER2/neu gene (1)
-
HER2+ breast cancer (6)
-
her2climb (1)
-
HER2-directed therapy (1)
-
her2-e (1)
-
HER2-negative (23)
-
HER2-negative breast cancer (1)
-
HER2-positive (15)
-
HER2-positive breast cancer (6)
-
HER2-targeted treatment (1)
-
her3 (1)
-
hera trial (1)
-
HERACLES (1)
-
Herbert Irving Cancer Center (1)
-
hereditary breast cancer (1)
-
hereditary multigene panels (1)
-
hereditary test (1)
-
Hernan Barangan (1)
-
heterogeneity (2)
-
HFRT (1)
-
HGBCL (1)
-
HIF2A (1)
-
high quality care (1)
-
high risk of dying (1)
-
high tumor burden (1)
-
high-dose interferon-α2b (2)
-
high-dose methotrexate (2)
-
high-dose radiation (1)
-
high-dose radiotherapy (1)
-
high-grade B cell lymphoma (1)
-
high-grade serous ovarian cancer (1)
-
highlights (2)
-
high-risk (2)
-
high-risk breast cancer (2)
-
high-risk disease (2)
-
high-risk head and neck cancer (2)
-
high-risk lung cancer (2)
-
high-risk myeloma (1)
-
high-risk neuroblastoma (1)
-
high-risk node negative (1)
-
high-risk patients (1)
-
high-risk prostate cancer (5)
-
high-risk renal cell carcinoma (2)
-
high-volume centers (3)
-
high-volume prostate cancer (1)
-
Hilary Adams (4)
-
Hilary Gan (1)
-
Hillard Lazarus (2)
-
Hind Rafei (1)
-
hippocampus (1)
-
Hispanic (1)
-
Hispanic breast cancer (1)
-
histology (1)
-
history of addiction (1)
-
HIV (1)
-
HL (1)
-
hla (1)
-
HNSCC (3)
-
Hodgkin lymphoma (15)
-
Holger Lode (2)
-
Holly Lawson (1)
-
homeless patients (1)
-
homologous recombination deficiency (1)
-
Hong Kong (1)
-
HOPE CRAIG (13)
-
Hope Haefner (1)
-
Hope Rugo (12)
-
hope s. rugo (2)
-
hopelessness (1)
-
hopes (1)
-
Hôpital de Hautepierre (1)
-
Hôpital Henri Mondor (1)
-
Hôpital Hôtel-Dieu (1)
-
Hôpital Le Bocage (2)
-
Hôpital Saint-Antoine (1)
-
Hôpital Saint-Louis (2)
-
hormonal therapy (3)
-
hormone naive prostate cancer (1)
-
hormone receptive (1)
-
hormone receptor (1)
-
hormone receptor positive (6)
-
hormone receptor status (1)
-
hormone receptor-positive (7)
-
hormone receptor–positive (3)
-
hormone receptor-positive breast (1)
-
hormone replacement (1)
-
hormone status (1)
-
hormone therapy (2)
-
hormone therapy naive (1)
-
hormone treatment (1)
-
hormone-naive disease (1)
-
hormones (1)
-
hormone-sensitive (3)
-
hormonotherapy (1)
-
hospice (2)
-
hospice care (2)
-
hospice referrals (1)
-
hospital admission (1)
-
hospital readmission (1)
-
Hospital Universitario 12 De Oct (4)
-
hospitalizations (1)
-
hot flashes (2)
-
HOVON-Nordic Lymphoma Group (1)
-
Howard Burris (3)
-
Howard Chazin (1)
-
Howard Kaufman (1)
-
Howard Sandler (8)
-
Howard Scher (3)
-
Howard West (2)
-
HPV (9)
-
HPV vaccine (3)
-
HPV-16 (1)
-
HPV-16 vaccine (1)
-
HPV-associated oropharyngeal squ (1)
-
HPV-positive oropharyngeal cance (1)
-
HR positive (1)
-
HR+ (1)
-
HR+ breast cancer (3)
-
HR+/HER2- (1)
-
HR+/HER2+ (2)
-
HR-positive (6)
-
HR-positive breast cancer (2)
-
Humaid Al-Shamsi (1)
-
human error (1)
-
human leukocyte antigen (1)
-
human papillomavirus (9)
-
humanitarian (1)
-
Huntsman Cancer Institute (6)
-
hyaluronidase (1)
-
hydrogel spacer (1)
-
Hyo Jin Ru (1)
-
hyperglycemia (1)
-
hypertension (2)
-
hyperthermic intraperitoneal (1)
-
hyperthermic intraperitoneal che (1)
-
hyperthermic intraperitoneal chemotherapy (1)
-
hypocalcemia (1)
-
hypofractionated (5)
-
hypofractioned radiotherapy (4)
-
hypomethylating agent (1)
-
hypomethylating agents (1)
-
HYPO-RT-PC trial (1)
-
hypoxia (1)
-
hypoxia-inducible factor 2 alpha (1)
-
hyprofractioned radiation (1)
-
hysterectomy (1)
-
IAEA trial (1)
-
IALSC 2015 (2)
-
Ian Chau (1)
-
ian e. krop (1)
-
Ian Krop (2)
-
Ian Yarett (6)
-
IASLC 2015 (22)
-
ibandronate (3)
-
Ibiayi Dagogo-Jack (1)
-
IBIS-1 study (1)
-
ibis-i trial (1)
-
ibis-ii (1)
-
ibrutinib (17)
-
ibrutinib resistance (1)
-
Icahn Mount Sinai School of Medi (1)
-
Icahn School of Medicine (1)
-
iCanCare study (1)
-
icaria-mm (1)
-
ice trial (1)
-
ICLIO (3)
-
ICON6 trial (1)
-
ICON8 trial (2)
-
idarubicin (1)
-
IDEA collaboration (1)
-
IDEA trial (2)
-
IDEAL trial (1)
-
idelalisib (2)
-
idh1 (1)
-
IDMC (1)
-
IFCT-1501 MAPS2 trial (2)
-
ifofsamide (1)
-
IGF/insulin signaling (1)
-
IGFR (1)
-
Ignacio Melero (4)
-
IGRT (1)
-
IMAB362 (1)
-
image-guided (1)
-
image-guided radiotherapy (1)
-
imaging (2)
-
imaging technique (1)
-
imetelstat (1)
-
immediate surgery (1)
-
IMmotion 151 (3)
-
IMMU-132 (1)
-
immune biomarker (1)
-
immune cells (3)
-
immune checkpoint (2)
-
immune checkpoint blockade (3)
-
immune checkpoint blockers (1)
-
immune checkpoint inhibitor (2)
-
immune checkpoint inhibitors (10)
-
immune dysfunction (1)
-
immune inhibitors (1)
-
immune microenvironment (2)
-
immune response (2)
-
immune system (1)
-
immune therapies (1)
-
immune thrombocytopenia (1)
-
immune-related (1)
-
immune-related adverse events (2)
-
immunity (1)
-
immunochemotherapy (3)
-
immunogenic (2)
-
immunogenic MSI tumor (1)
-
immunohistochemistry (1)
-
immunology (2)
-
immunomodulatory agents (1)
-
immuno-oncology (19)
-
immunoregulatory inhibition (1)
-
immunoscore (1)
-
immunosignatures (1)
-
immunotherapeutics (1)
-
immunotherapies (1)
-
immunotherapy (169)
-
Immunotherapy (92)
-
immunotherpy (1)
-
IMO Clinique de Genolier (1)
-
IMPACT study (1)
-
IMpassion 130 (2)
-
Imperial College London (1)
-
IMpower 130 (1)
-
IMpower131 trial (1)
-
improved quality of life (1)
-
improved survival (1)
-
improved workflow (1)
-
improving cancer care (1)
-
improving outcomes (1)
-
IMPT (1)
-
IMRT (7)
-
imspire170 (1)
-
IMvigor (1)
-
IMvigor 211 (1)
-
imvigor130 (1)
-
IMvigor210 trial (1)
-
in situ vaccine (1)
-
in-breast recurrence (1)
-
inclusion criteria (2)
-
Indiana University (1)
-
Indiana University Simon Cancer (2)
-
individualized treatment (1)
-
indolent lymphoma (1)
-
indolent lymphomas (1)
-
indolent NHL (1)
-
indolent non-Hodgkin lymphoma (1)
-
induction (2)
-
induction BCG therapy (1)
-
induction chemotherapy (1)
-
induction radiotherapy (1)
-
induction therapy (2)
-
induction treatment (1)
-
inequality of care (1)
-
infectious disease (2)
-
inflammation (2)
-
inflammatory breast cancer (2)
-
infrastructure (1)
-
Inga Lennes (1)
-
Ingrid Mayer (3)
-
inhibitory receptor expression (1)
-
initial therapy (2)
-
inotuzumab (2)
-
inotuzumab ozogamicin (1)
-
INSERM (4)
-
insomnia (2)
-
Institut Curie (1)
-
Institut Curies (1)
-
Institut Gustave Roussy (8)
-
Institut Jules Bordet (1)
-
Institut Régional du Cancer (1)
-
Institute for Clinical Evaluativ (1)
-
Institute of Cancer Research (3)
-
Institute of Cancer Research Lon (1)
-
Institute of Clinical Cancer Res (1)
-
Institute of Medicine (1)
-
Institute of Medicine report (1)
-
Instituto Nazionale Tumori-Fonda (2)
-
insulin (1)
-
insurance (1)
-
integrated care (1)
-
integrating palliative care (1)
-
integration of palliative care (2)
-
intensity modulated proton thera (1)
-
intensity-modulated (1)
-
intensity-modulated radiotherapy (1)
-
intensive chemotherapy (1)
-
interaperitoneal (1)
-
interferon gamma (1)
-
interleukin 12 (1)
-
intermediate-risk (2)
-
intermediate-risk prostate cance (1)
-
international oncology (3)
-
international standards (1)
-
interpretation (1)
-
intervention (1)
-
interventional (1)
-
intracranial disease (1)
-
intracranial response (2)
-
intraoperative peritoneal lavage (1)
-
intraperitoneal (1)
-
intraperitoneal chemotherapy (2)
-
intraperitoneal immunotherapy (1)
-
intratumoral (1)
-
intravascular DLBCL (1)
-
intravenous (1)
-
intravenous chemotherapy (2)
-
intrinsic expression subtype (1)
-
invasive breast cancer (2)
-
investigator-choice chemotherapy (1)
-
involved field irradiation (1)
-
ipatasertib (1)
-
ipilimumab (27)
-
ipilimumab-refractory (1)
-
ipilumumab (5)
-
IPOS APOS 2015 (6)
-
IPOS-APOS 2015 (11)
-
IPOS-APOS 2015. Andrea Patenaude (1)
-
Ira Byock (1)
-
Irad Deutsch (1)
-
iRAE (2)
-
Irene Higginson (2)
-
irinotecan (4)
-
IROCK study (1)
-
ISA101 (1)
-
Isabel Arrellaga-Romany (1)
-
Isacco Montroni (1)
-
isatuximab (1)
-
ischemic stroke (1)
-
Ishwaria M. Subbiah (1)
-
Ismail Jatoi (3)
-
Issues in Oncology (18)
-
Istituto Nazionale dei Tumori (4)
-
Istituto Toscano Tumori-Ospedale (1)
-
italy (1)
-
iv paclitaxel (1)
-
ivosidenib (1)
-
IVY DUNEIER (1)
-
IWWD.org (1)
-
ixabepilone (1)
-
ixazomib (3)
-
J. Gregory Mears (1)
-
J. Nicholas Dionne-Odom (1)
-
Jaafar Bennouna (1)
-
Jacek Jassem (2)
-
Jack B. Fu (1)
-
Jack Cuzick (4)
-
Jack Gentile (1)
-
Jack Lambert (1)
-
Jacob Laubach (1)
-
Jacob Rowe (1)
-
Jacob Strand (1)
-
Jaffer Ajani (2)
-
JAK inhibitor (2)
-
JAK2 inhibitor (1)
-
Jame Abraham (21)
-
James A. Stewart (1)
-
James Abbruzzese (3)
-
James Armitage (26)
-
James Armitage Hagop Kantarjian (1)
-
James Berenson (1)
-
James Cancer Center (1)
-
James Cancer Hospital (1)
-
James Cleary (1)
-
James Doroshow (2)
-
James F. Holland (3)
-
James Foran (2)
-
James Gould (1)
-
James Hillard (1)
-
James Jett (2)
-
James Kochenderfer (4)
-
James Mohler (1)
-
James Mulshine (10)
-
James O. Armitage (3)
-
James P. Stevenson (1)
-
James Perry (1)
-
James Rubenstein (1)
-
James Smithy (1)
-
James W. Lynch (1)
-
James Yu (2)
-
Jamie H. Von Roenn (1)
-
Jamie Jacobs (1)
-
Jamil Aliyev (1)
-
Jamil Rivers (1)
-
Jan Buckner (2)
-
Jan Oosterwijk (1)
-
Jane Greene (1)
-
Jane Gutkovich (2)
-
Jane McNeil Beith (1)
-
Jane Winter (1)
-
Janessa Laskin (1)
-
Janet Klein (1)
-
Janet Snapp (1)
-
Janet Weinberg (1)
-
Janet Wohlmacher (1)
-
Janice Dutcher (1)
-
Janine Overcash (5)
-
Japan Clinical Oncology Group (1)
-
Jasenka Piljac Žegarac (9)
-
Jasmine M. Wong (1)
-
Jason Gotlib (1)
-
Jason Zimmermann (1)
-
JAVELIN (1)
-
javelin renal 101 (1)
-
JAVELIN study (1)
-
Javier Cortes (1)
-
Jay Harris (5)
-
Jay R. Harris (1)
-
JCOG1001 (1)
-
JD (1)
-
Jean Connors (1)
-
Jean M. Connors (5)
-
Jean-Charles Soria (6)
-
Jean-Michel Hannoun-Levi (1)
-
JEANNETTE PARKES (1)
-
Jeannine Nonaillada (1)
-
Jeannine Walston (1)
-
Jean-Yves Douillard (2)
-
Jedd Wolchok (6)
-
Jeff Boyd (1)
-
Jeff Dunn (4)
-
Jeff Summers (1)
-
Jeffrey Bradley (1)
-
Jeffrey Crawford (1)
-
Jeffrey Groeger (1)
-
Jeffrey Jones (1)
-
Jeffrey Lancet (1)
-
Jeffrey Patton (1)
-
Jeffrey Schneider (1)
-
Jeffrey Weber (1)
-
Jennifer Brown (2)
-
Jennifer Brudno (1)
-
Jennifer Gao (1)
-
Jennifer Ho (1)
-
Jennifer King (2)
-
Jennifer Legible (1)
-
Jennifer Ligibel (2)
-
Jennifer Litton (1)
-
Jennifer Lycette (2)
-
Jennifer Mack (1)
-
Jennifer Nam Choi (1)
-
Jennifer Temel (4)
-
Jennifer Titche (1)
-
Jennifer Wargo (1)
-
Jennifer Woyach (4)
-
Jenny Ahlstrom (1)
-
Jens Huober (1)
-
Jenske Geerling (1)
-
Jeong-Seon Ryu (1)
-
Jerald Radich (5)
-
Jerald Varner (1)
-
Jeremy Hirst (1)
-
Jeremy Hon (1)
-
Jeremy Pivor (1)
-
Jeremy Warner (1)
-
Jeri Dyson (1)
-
Jerome Yates (1)
-
Jeromie Ballreich (1)
-
Jesse McGreivy (1)
-
Jessica Boehmer (1)
-
Jessica Nye (1)
-
Jessica Scott (2)
-
Jessica Wu (1)
-
Jesuel Padro-Guzman (1)
-
Jill Lacy (1)
-
Jim Armitage (2)
-
Jim Mulshine (1)
-
Jim Omel (2)
-
Jim Taulman (1)
-
Jim Turner (1)
-
Jimmie Harvey (1)
-
Jimmie Holland (7)
-
Jinane Kharmoum (1)
-
jipang trial (1)
-
jo (1)
-
Jo Cavallo (1106)
-
Joachim Yahalom (1)
-
Joanne Mortimer (2)
-
Joanne Weidhaas (1)
-
Jocelyn Ray (1)
-
Jocelyn Solis-Moreira (2)
-
Jodi MacLeod (1)
-
Joel Tepper (2)
-
John A. Thompson (1)
-
John Cox (2)
-
John F. Thompson (1)
-
John Fracchia (1)
-
John Gentile Jr (1)
-
John Gerecitano (2)
-
John Goodman (2)
-
John Grecula (2)
-
John Gribben (1)
-
John H. Stewart (1)
-
John Hainsworth (1)
-
John Jakob (1)
-
John L. Marshall (1)
-
John Leonard (2)
-
John Macdonald (1)
-
John Marshall (10)
-
John Neoptolemos (1)
-
John Pagel (2)
-
John Peters (1)
-
John Primrose (1)
-
John Smyth (12)
-
John Suh (1)
-
John Thompson (1)
-
John Williams (1)
-
JOHNNY BORGSTROM (1)
-
Johns Hopkins (6)
-
Johns Hopkins Bloomberg School o (1)
-
Johns Hopkins Kimmel Cancer Center (1)
-
Johns Hopkins Medicine (1)
-
Johns Hopkins School of Medicine (1)
-
Johns Hopkins Sidney Kimmel Cancer Center (1)
-
Johns Hopkins University (3)
-
Joke Bradt (2)
-
Joleen Hubbard (1)
-
Jonas de Souza (1)
-
Jonathan Cohen (1)
-
Jonathan Cotliar (2)
-
Jonathan Friedberg (3)
-
Jonathan L. Finlay (1)
-
Jonathan Ledermann (2)
-
Jonathan Lewis (1)
-
Jonathan R. Strosberg (1)
-
Jonathan Rosenberg (5)
-
Jonathan Schwartz (3)
-
Jonathan Strosberg (2)
-
JONATHAN W. FRIEDBERG (1)
-
Jonathon Cohen (2)
-
Jordan Holmes (1)
-
Jorg Dietrich (1)
-
Jorge Cortes (3)
-
Jorge Reis-Filho (1)
-
Jose Karam (1)
-
Jose Leis (1)
-
Josep Llovet (2)
-
Joseph B. Narus (1)
-
Joseph Bailes (1)
-
Joseph Connors (3)
-
Joseph Cupolo (1)
-
Joseph Greer (1)
-
Joseph Jacobson (2)
-
Joseph Mason (1)
-
Joseph Simone (1)
-
Joseph Sparano (4)
-
Joseph V. Simone (1)
-
Joseph V. Simone Award (2)
-
Josh Mailman (1)
-
Joshua Armenia (1)
-
Joshua Brody (1)
-
Joshua Drago (1)
-
Joshua Lang (1)
-
Joshua Spendlove (1)
-
JOYCE KURISKO (1)
-
Joyce Liu (2)
-
Jr (1)
-
Juan Chipollini (1)
-
Juanita Crook (1)
-
Judd Moul (1)
-
Judith Balmana (2)
-
Judith Malmgren (1)
-
Judith Paice (3)
-
Judith Vick (2)
-
Judy Garber (5)
-
Judy Perkins (1)
-
Jules Bordet Institute (2)
-
Julia Fehniger (1)
-
Julia Rowland (2)
-
Julia White (2)
-
Julie A. Schneider (1)
-
Julie Bryar Porter (1)
-
Julie Bullock (1)
-
Julie Gralow (6)
-
Julie Lemieux (2)
-
julie m. vose (3)
-
Julie Miller (1)
-
Julie Nangia (1)
-
Julie Park (1)
-
Julie Silver (1)
-
Julie Vose (34)
-
Julien Edeline (2)
-
Julienne Bower (1)
-
JULIET trial (1)
-
Jun J. Mao (5)
-
Jun Mao (13)
-
Jung-min Lee (1)
-
Justin Brown (1)
-
Justin Gainor (1)
-
Jyothirmai Gubili (71)
-
K. Holly Mead (1)
-
K. Simon Yeung (2)
-
Kah Poh (Melissa) Loh (2)
-
Kah Poh Melissa Loh (1)
-
Kaiser Permanente (1)
-
Kamal Menghrajani (1)
-
Kamran Ahmed (1)
-
Karen Colbert Maresso (1)
-
Karen Daily (1)
-
KAREN E. KNUDSEN (1)
-
Karen Fasciano (2)
-
Karen J. Krag (1)
-
Karen Kelly (3)
-
Karen Knudsen (1)
-
Karen Lisa Smith (2)
-
Karen Marcus (1)
-
Karen Merlino (1)
-
Karen Nestor (1)
-
Karen Peterson (1)
-
Karen Popkin (4)
-
Karen Reckamp (1)
-
Karen Winkfield (1)
-
Karim Chamie (1)
-
Karim Fizazi (4)
-
Karim Touijer (1)
-
Karl Lewis (1)
-
Karl Schwartz (2)
-
Karuna Ganesh (1)
-
Karyn Goodman (1)
-
Katarzyna Jerzak (1)
-
kate2 (1)
-
Katharina Fleischhauer (2)
-
Katherine Crawford (2)
-
Katherine Crew (1)
-
Katherine H. Crawford (2)
-
Katherine Reeder-Hayes (2)
-
KATHERINE trial (1)
-
Kathleen Bickel (1)
-
Kathleen Cathcart (1)
-
Kathleen Elizabeth Bickel (1)
-
Kathleen Foley (2)
-
Kathleen Moore (2)
-
Kathleen Pritchard (2)
-
Kathleen Ruddy (1)
-
Kathleen Uhl (1)
-
Kathleen Wesa (5)
-
Katholieke Universiteit Leuven (1)
-
Kathryn Desimone (1)
-
Kathryn E. Hitchcock (1)
-
Kathryn Hudson (1)
-
Kathryn Mileham (1)
-
Kathryn Roberts (1)
-
Kathryn Ruddy (1)
-
Kathryn Sommer (1)
-
Kathy Albain (2)
-
Kathy Giusti (3)
-
Kathy Holliman (2)
-
Kathy Miller (1)
-
Katie Greenzang (1)
-
Katja Wiesel (2)
-
Kavita Dharmarajan (1)
-
Kavita Mishra (1)
-
Kavita Yadav (2)
-
Keegan Bales (9)
-
Keith Flaherty (2)
-
keith mccrae (6)
-
Kelly Cotton (1)
-
KELLY HEWITT (1)
-
Kelly Trevino (1)
-
Ken Anderson (1)
-
Keneene Lewis (1)
-
Kenneth Anderson (10)
-
Kenneth Foon (1)
-
Kenneth L. Kehl (1)
-
Kenneth R. Adler (1)
-
Kerin Adelson (2)
-
Kerri Winters-Stone (2)
-
Kevin B. Knopf (1)
-
Kevin Knopf (1)
-
Kevin Krull (1)
-
Kevin Liou (2)
-
Kevin Oeffinger (3)
-
KEVIN T. LIOU (2)
-
Kevin Weinfurt (1)
-
KEYNOTE 014 (1)
-
keynote 119 (1)
-
keynote trial (2)
-
KEYNOTE trials (1)
-
KEYNOTE-001 (2)
-
KEYNOTE-002 (1)
-
KEYNOTE-028 (2)
-
KEYNOTE-028 study (1)
-
KEYNOTE-042 (1)
-
KEYNOTE-045 (1)
-
KEYNOTE-045 trial (1)
-
keynote-048 (1)
-
KEYNOTE-052 (1)
-
KEYNOTE-057 (1)
-
keynote-062 (1)
-
keynote-158 (1)
-
keynote-181 (1)
-
KEYNOTE-224 (1)
-
keynote-426 (2)
-
KEYNOTE-427 (2)
-
keynote-522 (1)
-
Khalid El Bairi (5)
-
Khalid El Bairi, Dounia Filali, Nabil Ismaili, Zouhour Bourhaleb, Ali Sbai, Mohamed Marjani, Zineb Benbrahim, Meriem Iraqi Houssaini, Mohamed Mesmoudi (1)
-
Khalid Halahleh (1)
-
Khalid Rehman (3)
-
kidney cancer (54)
-
Kidney Cancer (15)
-
Kids v Cancer (1)
-
Kieron Dunleavy (4)
-
killer-cell Ig-like receptor gen (2)
-
Kim A. Margolin (1)
-
Kim Leary (1)
-
Kim Polacek (1)
-
Kimberley Lee (1)
-
Kimberley T. Lee (1)
-
Kimberly Boldig (1)
-
Kimmie Ng (3)
-
kinase targets (1)
-
kindly cancer (3)
-
Kings College Hospital (1)
-
Kirby Lewis (1)
-
Kirsten Boyd Goldberg (14)
-
Kishore Dass (1)
-
Kishwer Nehal (1)
-
KLAUS PUSCHEL (1)
-
Koh (1)
-
Konrad Stopsack (1)
-
Koshy Alexander (1)
-
Krankenhaus Nordwest (1)
-
KRAS (3)
-
KRAS mutations (1)
-
Krishna Gundabolu (1)
-
Krishnansu Tewari (2)
-
Kristen Spencer (1)
-
Kristen Whitaker (1)
-
kristine trial (1)
-
Krzysztof Bujko (2)
-
Kwok-Leung Cheung (1)
-
Kyle Rove (1)
-
L. Elizabeth Budde (2)
-
L. Jeffrey Medeiros (19)
-
L. Michael Glode (1)
-
lack of medical resources (1)
-
lack of resources (1)
-
Lacouture (1)
-
Lancaster General Hospital (1)
-
Lanie Brewster Quinn (1)
-
laparoscopic (2)
-
lapatinib (4)
-
Lara Benusis (2)
-
large B cell lymphoma (1)
-
large cell neuroendocrine lung t (1)
-
larotrectinib (1)
-
Larry Leichman (1)
-
Larry Rosenberg (5)
-
Larry Slavens (1)
-
Larry Weisenthal (3)
-
Larry Wickerham (2)
-
laryngeal cancer (1)
-
laryngeal preservation (1)
-
late effects (3)
-
late recurrence (1)
-
late side effects (1)
-
late stage melanoma (1)
-
late toxicity (1)
-
late-stage cancer (2)
-
late-stage colon cancer (1)
-
Latin America (1)
-
Latino breast cancer (1)
-
LATITUDE trial (4)
-
Laura A. Levit (1)
-
Laura Esserman (1)
-
Laura Greco (1)
-
LAURA J. ESSERMAN (1)
-
Laura Leavit (1)
-
Laura Melton (1)
-
Laura Panattoni (1)
-
Laura Q.M. Chow (1)
-
Laura Rooms (1)
-
Laura Veneroni (1)
-
Laura Williams Goff (1)
-
Lauren Davis (3)
-
Lauren Hotaki (1)
-
Lauren Wallner (1)
-
Laurence H. Baker (4)
-
Laurie Gaspar (1)
-
Laurie Helen Sehn (1)
-
Laurie Lyckholm (1)
-
Laurie MacCaskill (1)
-
Laurie Sehn (14)
-
law (3)
-
Lawrence Einhorn (6)
-
Lawrence Feldman (1)
-
Lawrence Fong (1)
-
Lawrence Shulman (5)
-
Leah Christl (1)
-
Leah Lawrence (11)
-
lean body mass (3)
-
Lee Jones (1)
-
Lee Krug (1)
-
Lee Newcomer (4)
-
Lee Schwartzberg (11)
-
Leena Gandhi (1)
-
left side tumor (1)
-
left ventricular ejection fratio (1)
-
legal issues (2)
-
Legislation (2)
-
Leiden University Medical Center (1)
-
Leiden University Medical Centre (1)
-
Leigh Leibel (1)
-
leiomyosarcoma (2)
-
Leisha Emens (1)
-
lenalidomide (22)
-
lenaliodmide (1)
-
length of treatment (1)
-
lenvatinib (4)
-
Leo Gordon (3)
-
Leonard Berry (1)
-
Leonard Gunderson (2)
-
Leonard Saltz (5)
-
Leonard Zwelling (1)
-
Leora Horn (2)
-
Lesa Kirkman (1)
-
lethal prostate cancer (2)
-
letrozole (9)
-
leucovorin (2)
-
leukemia (42)
-
Leukemia (16)
-
Levine Cancer Institute (5)
-
levothyroxine (1)
-
Lewis Foxhall (2)
-
Lewis Roberts (1)
-
lgbtq (2)
-
LGBTQ patients (1)
-
LHRH agonists (1)
-
Lia Halasz (1)
-
Libia Scheller (1)
-
Lida Zheng (1)
-
Lidia Schapira (2)
-
life expectancy (1)
-
Life Interrupted (1)
-
lifestyle (1)
-
lifestyle change (1)
-
lifestyle recommendations (1)
-
limited-stage disease (1)
-
Limo Chen (1)
-
Linda Burns (2)
-
Linda Carlson (5)
-
linda j. burns (6)
-
Linda McDonald (1)
-
Linda T. Vahdat (1)
-
Linda Van Le (1)
-
Lindi Campbell (1)
-
Linnea Olson (1)
-
liposome (1)
-
liquid biopsy (3)
-
lisa a. carey (3)
-
Lisa Arzola (1)
-
Lisa Carey (25)
-
Lisa Carey MD (1)
-
Lisa DeAngelis (1)
-
Lisa Diller (3)
-
Lisa Marie Ruppert (1)
-
Lisa Mendelson (1)
-
Lisa Newman (1)
-
Lisa Diller (1)
-
lisocabtagene maraleucel (1)
-
Lital Keinan-Boker (2)
-
liver cancer (15)
-
liver metastases (6)
-
liver SBRT (1)
-
liver-directed therapy (1)
-
living with cancer (1)
-
Liz Janetschek (84)
-
Liz Janetschek Pasini (5)
-
Liz Pasini (16)
-
Liza Marshall (1)
-
local control (4)
-
local disease (2)
-
local recurrence (1)
-
local therapy (1)
-
localized disease (1)
-
localized high risk (1)
-
localized prostate cancer (4)
-
localized rectal cancer (1)
-
locally advanced (2)
-
locally advanced breast cancer (3)
-
locally advanced cancer (1)
-
locally advanced disease (1)
-
locally recurrent breast cancer (1)
-
locoregional (1)
-
locoregional treatment (4)
-
locoregionally recurrent breast (1)
-
Lodovico Balducci (9)
-
Lois Ramondetta (1)
-
Lombardi Cancer Center (4)
-
lomustine (1)
-
London Health Sciences Centre (1)
-
long-term ADT (1)
-
long-term morbidity (1)
-
long-term mortality (1)
-
long-term overall survival (1)
-
long-term results (1)
-
long-term sequelae (1)
-
long-term side effects (1)
-
long-term survival (2)
-
long-term therapy (1)
-
Lora Thompson (1)
-
Lorenzo Cohen (6)
-
Lori Alf (1)
-
Lori Goldstein (2)
-
Lori J. Wirth (1)
-
Lori Pierce (6)
-
Lori Wiener (4)
-
Lori Wirth (3)
-
Loriana Hernandez-Aldama (1)
-
Lorraine Egan (1)
-
Lorraine McEvoy (1)
-
Lorraine Pelosof (2)
-
Los Angeles (1)
-
loss (1)
-
loss of a child (1)
-
loss of dignity (1)
-
loss of muscle (1)
-
LOTUS trial (1)
-
Lou Vaickus (1)
-
Louis Burt Nabors (1)
-
Louis Harrison (1)
-
Louis Staudt (1)
-
Louise Cooper (1)
-
low dose screening (1)
-
low HER2-expressing (1)
-
low income country (1)
-
low resource setting (1)
-
low-dose chemotherapy (2)
-
low-dose CT (1)
-
low-dose CT screening (1)
-
Lowell Kleinman (1)
-
lower gastrointestinal cancer (1)
-
lower mortality (1)
-
lower-income patients (1)
-
low-fat diet (2)
-
low-grade glioma (1)
-
low-income (2)
-
low-income country (1)
-
low-literacy patients (1)
-
low-risk (2)
-
low-risk prostate cancer (1)
-
low-value care (1)
-
low-volume prostate cancer (1)
-
Loyola University Medical Center (1)
-
Lu Daopei Hospital (1)
-
Lu-177 dotatate (1)
-
Lucas Dean (1)
-
Luciano Costa (2)
-
Lucy Pickard (1)
-
Ludwig Maximilian University of Munich (2)
-
Luis A. Diaz (1)
-
Luis Alejandro Salicrup (1)
-
Luis E. Pino (2)
-
LUIS EDUARDO PINO VILLARREAL (1)
-
Luis Meza (1)
-
Luis Paz-Ares (6)
-
Lukas Wartman (1)
-
luminal A (1)
-
luminal type breast cancer (1)
-
lumpectomy (3)
-
lung cancer (121)
-
Lung Cancer (43)
-
Lung Cancer Alliance (1)
-
lung cancer risk (1)
-
lung cancer screening (3)
-
lung cancer staging (1)
-
lung cancer workup (1)
-
lung dose (1)
-
lung toxicity (1)
-
LungenClinic (3)
-
LUNGMAP (1)
-
lupus (1)
-
lurbinectedin (3)
-
Lurie Comprehensive Cancer Cente (1)
-
luspatercept (1)
-
LUX-Lung 7 Trial (2)
-
LUX-Lung 8 (1)
-
LY2606368 (1)
-
LYDIA CAIRNCROSS (1)
-
LyMa trial (2)
-
lymph node (2)
-
lymph node assessment (1)
-
lymph node dissection (2)
-
lymph node surgery (1)
-
lymph nodes (1)
-
lymphadenectomy (2)
-
lymphedema (1)
-
lymphoblastic leukemia (1)
-
lymphocytes (1)
-
lymphocytic infiltration (1)
-
lymphoid malignancies (2)
-
lymphoma (72)
-
Lymphoma (19)
-
lymphoma survivors (1)
-
lymphomas (1)
-
lymphoplasmacytic lymphoma (1)
-
lynch syndrome (1)
-
Lynda Balneaves (1)
-
Lynn Cancer Institute (1)
-
Lynn Sage Comprehensive Breast C (1)
-
LYNN SCHUCHTER (1)
-
Lynn Volk (1)
-
Lynne Lederman (1)
-
Lysa Remarc Study (1)
-
Lysa Remarc trial (1)
-
Lysa study (2)
-
M D Anderson (1)
-
M. Catherine Pietanza (2)
-
M. Gregg Bloche (1)
-
M. Shaalan Beg (1)
-
M. Steven Piver (2)
-
MA20 (1)
-
Mace Rothenberg (1)
-
Mafalda Von Alvensleben (1)
-
magnetic resonance imaging (2)
-
Maha Hussain (5)
-
Mahmoud Al-Hawary (1)
-
MAIA trial (1)
-
maintenance (1)
-
maintenance BCG therapy (1)
-
maintenance monotherapy (1)
-
maintenance therapy (5)
-
Mairéad Geraldine McNamara (1)
-
Maki Tania (1)
-
male patients (1)
-
Malgorzata Mikulska (1)
-
mammography (2)
-
mammography guidelines (1)
-
management of lung cancer (1)
-
Managing Editor (1)
-
managing toxicities (1)
-
Manali Patel (2)
-
Mani Menon (1)
-
Manish Shah (1)
-
Manisha H. Shah (1)
-
Manisha Shah (2)
-
Mansoor Mirza (1)
-
Mansoor Raza Mirza (2)
-
mantle cell (1)
-
mantle cell lymphoma (11)
-
Manuel Hidalgo (1)
-
Manuj Agarwal (3)
-
Marc Lawler (1)
-
Marc R. Theoret (1)
-
Marc Theoret (1)
-
Marc Ychou (1)
-
Marcel Rozencweig (1)
-
Marcel Verheij (1)
-
Marci Greenberg Cox (1)
-
Marcus Randall (1)
-
Margaret A. Tempero (1)
-
Margaret Callahan (1)
-
Margaret Hamburg (1)
-
Margaret Kasner (1)
-
Margaret O’Donnell (1)
-
Margaret O'Donnell (1)
-
Margaret Tempero (3)
-
Margaret von Mehren (2)
-
Margaret Werts (1)
-
margetuximab (2)
-
marginal zone lymphoma (1)
-
Margot Fromer (2)
-
Margot J. Fromer (55)
-
Maria Cabanillas (1)
-
Maria Clemence Schwaederle (1)
-
Maria Sklodowska Curie Cancer Ce (1)
-
Maria Werner-Wasik (2)
-
Mariame Chraibi (1)
-
Mariana Figueiro (1)
-
Marie Bleakley (1)
-
Marie Elaine Price-Lockridge (1)
-
Marie Krejci (1)
-
Marie Sabo Recine (6)
-
Marie-Andree Forget (1)
-
Mario E. Lacouture (6)
-
Mario Sznol (4)
-
marital status (1)
-
Marjory Charlot (1)
-
Mark Helvie (1)
-
Mark Lazenby (2)
-
Mark Lewis (1)
-
Mark McCamish (1)
-
Mark R. Gilbert (1)
-
Mark Ratain (3)
-
Mark Robson (2)
-
Mark Roschewski (2)
-
Mark Smith (1)
-
Mark Talamonti (1)
-
Mark Trombetta (1)
-
marker decline (1)
-
Marleen Kok (1)
-
Marlise R. Luskin (1)
-
Marseille Cancer Center (2)
-
Marsha Axler (1)
-
Marsha Edwards (1)
-
Martee Hensley (1)
-
Martha Donoghue (1)
-
Martha Tracy (1)
-
Martin Edelman (1)
-
Martin Reck (2)
-
Martin Schrappe (2)
-
Martin Schuler (2)
-
Martin Tallman (3)
-
Martin Van Den Vent (1)
-
Martine Extermann (1)
-
Martine Frouws (2)
-
Martine Piccart (1)
-
Martine Piccart-Gebhart (5)
-
Marvin Stone (1)
-
Marwan Fakih (1)
-
MARY ALMA WELCH (1)
-
Mary B. Daly (1)
-
Mary Bridge Children's Hospital (1)
-
Mary Evelyn Burman (1)
-
Mary Gospodarowicz (6)
-
Mary Longhini (1)
-
Mary Lou Smith (2)
-
Mary McCabe (6)
-
MARY MULCAHY (1)
-
Mary Pasquinelli (1)
-
Mary Vargo (1)
-
Masanori Terashima (1)
-
Mass Gen (2)
-
Massachusetts General (7)
-
Massachusetts General Hospital (14)
-
massage (1)
-
Massimo Cristofanilli (2)
-
mastectomy (5)
-
MATCH trial (1)
-
Matt Ellefson (1)
-
Matt Kalaycio (1)
-
Matt Lunning (1)
-
Matteo Lambertini (3)
-
Matteo Silva (1)
-
Matthew Ellis (6)
-
Matthew Galsky (1)
-
Matthew Goetz (1)
-
Matthew Hellmann (1)
-
matthew j. ellis (1)
-
Matthew J. Resnick (1)
-
Matthew Loscalzo (2)
-
matthew lunning (5)
-
Matthew Smith (2)
-
Matthew Stenger (4217)
-
MATTHEW ZIBELMAN (1)
-
Matti Aapro (7)
-
Maura Dickler (3)
-
Maura Gillian (1)
-
Maura Gillison (2)
-
Maura Massimino (1)
-
Maureen Markham (1)
-
Maureen Roberts (1)
-
Maurie Markman (2)
-
MAVERICC study (2)
-
Maximilian Diehn (1)
-
Maxwell Krem (1)
-
Mayo Clinc Cancer Center (3)
-
Mayo Clinic (35)
-
Mazie Tsang (1)
-
MBA (1)
-
MBBCh (1)
-
mbc (1)
-
MBChB (1)
-
mcc (1)
-
McGill (3)
-
mcguire lecture (1)
-
MCL (6)
-
McMaster University (2)
-
mcrc (1)
-
mcrpc (1)
-
MD (12)
-
MD Abdul Wadud Khan (1)
-
MD Anderson (23)
-
MD Anderson Cancer Center (14)
-
MD; Lola Fashoyin-Aje (1)
-
MD; Marc R. Theoret (1)
-
MD; Martha B. Donoghue (1)
-
MD; Paul G. Kluetz (1)
-
MD; Richard Pazdur (1)
-
MDS (5)
-
meaning centered psychotherapy (4)
-
meaning centered therapy (1)
-
MEC inhibitor (1)
-
Medalist trial (1)
-
medicaid (1)
-
Medicaid expansion (1)
-
medical burden (1)
-
Medical College of Wisconsin (1)
-
medical complications (2)
-
medical fellows (1)
-
medical fellowship (1)
-
medical oncologist (1)
-
medical oncology (1)
-
Medical Oncology Rosebank (1)
-
medical reporting (1)
-
Medical University of Vienna (2)
-
Medical University Vienna – Ge (1)
-
medicare (1)
-
medication adherence (1)
-
meditation (1)
-
medullary (1)
-
Meena Moran (1)
-
Meena S. Moran (2)
-
Meg Barbor (144)
-
Meg O'Brien (1)
-
Megan Caram (1)
-
Megan Daly (1)
-
Mehment Sitki Copur (1)
-
Melanie E. Royce (1)
-
Melanie Royce (2)
-
Melanie Seal (1)
-
melanoma (34)
-
Melanoma (2)
-
Melanoma Institute Australia (2)
-
melanoma survivor (1)
-
melflufen (1)
-
Melinda Bachini (1)
-
Melinda Telli (1)
-
Melissa Crouse (1)
-
Melissa Fryman (1)
-
Melissa Johnson (1)
-
Melissa McShane (1)
-
melphalan (1)
-
Memorial Sloan Kettering (78)
-
Memorial Sloan Kettering Cancer (2)
-
Memorial Sloan Kettering Cancer Center (26)
-
men (1)
-
meningioma (1)
-
menopausal symptoms (1)
-
menopause (2)
-
men's health (1)
-
mental health (2)
-
mental health status (1)
-
mental illness (1)
-
mentee (1)
-
mentor (2)
-
mentorship (3)
-
Meredith Baker (1)
-
merkel cell carcinoma (3)
-
Merrick I. Ross (1)
-
mesothelioma (3)
-
MET amplification (1)
-
MET mutation (2)
-
metabolic syndrome (3)
-
metastasectomy (2)
-
metastases (1)
-
metastasis (3)
-
metastasis free survival (1)
-
metastasis score (1)
-
metastatic (20)
-
metastatic bladder cancer (2)
-
metastatic breast cancer (20)
-
metastatic burden (1)
-
metastatic cancer (9)
-
metastatic cancer care (1)
-
metastatic cancer pain (1)
-
metastatic castration-resistant prostate cancer (1)
-
metastatic colon cancer (1)
-
metastatic colorectal cancer (9)
-
metastatic disease (3)
-
metastatic head and neck cancer (1)
-
metastatic hormone-naive prostat (1)
-
metastatic lung cancer (3)
-
metastatic melanoma (4)
-
metastatic nsclc (1)
-
metastatic prostate cancer (3)
-
metastatic renal cell carcinoma (1)
-
metastatic solid cancer (2)
-
metastatic solid tumors (1)
-
metastatic spinal cord compressi (1)
-
metastatic tumors (1)
-
metastatic urothelial cancer (1)
-
metastatic urothelial carcinoma (1)
-
METEOR trial (4)
-
metformin (2)
-
methotrexate (1)
-
methylation (1)
-
mFFOX (1)
-
mFOLFIRINOX (2)
-
mfolfox6 (2)
-
mFOLFOX6-bevacizumab (2)
-
Mhairi Copland (1)
-
mibc (2)
-
Michael Alvarado (1)
-
Michael Becker (3)
-
Michael Bookman (1)
-
Michael Cecchini (2)
-
Michael Davies (1)
-
Michael E. Williams (1)
-
Michael Feinstein (1)
-
Michael Fisch (1)
-
Michael Gnant (2)
-
Michael Green (1)
-
Michael Hoerger (1)
-
Michael Irwin (1)
-
Michael J. Hall (1)
-
Michael J. Overman (2)
-
Michael K. Gibson (1)
-
Michael Kraut (1)
-
Michael LeFevre (1)
-
Michael Link (1)
-
Michael Mauro (1)
-
Michael Overman (1)
-
Michael Perrotta (1)
-
Michael Pfreundschuh (2)
-
Michael Postow (3)
-
Michael Sabel (2)
-
Michael Schweizer (1)
-
Michael Stubblefield (1)
-
Michael T. Schweizer (1)
-
Michael Thompson (1)
-
Michael Van Scoy-Mosher (1)
-
Michael Wang (1)
-
Michel Ducreux (2)
-
Michela Casanova (1)
-
Michele Beau-Faller (1)
-
Michele Cavo (2)
-
Michele Schuman (1)
-
Michelle Dalton (1)
-
Michelle LeBeau (1)
-
Michelle Lynn Mierzwa (1)
-
microbes (1)
-
microbiota (1)
-
microsatellite instability (4)
-
microsatellite instability high (1)
-
microsatellite instability-high (1)
-
microsatellite stable (1)
-
middle income country (1)
-
middle-income country (1)
-
midgut (1)
-
midgut tumors (1)
-
midostaurin (1)
-
Miguel-Angel Perales (1)
-
Mike Armstrong (1)
-
Mikkael A. Sekeres (2)
-
Mikkael Sekeres (3)
-
MIKRAM KHARMACH (1)
-
Milan Anadkat (2)
-
Milena Sant (2)
-
Milind Javle (1)
-
Mindy Greenstein (2)
-
Mindy Tanzola (10)
-
Mingzhao Xing (1)
-
minimal residual disease (4)
-
minimally invasive (3)
-
minimally invasive surgery (1)
-
minority (1)
-
minority patients (1)
-
Mirat Shah (1)
-
Miri Ziv (2)
-
Miriam A. Knoll (1)
-
mirvetuximab soravtansine (1)
-
Mischa P. M. Nagel (1)
-
misdiagnosis (1)
-
mismatch repair (2)
-
mismatch repair deficiency (1)
-
mismatch repair-deficient (1)
-
mismatched repair genes (1)
-
missed appointments (1)
-
MIT (1)
-
Mitchell Cairo (2)
-
Mitchell Chan (1)
-
Mitchell Dowsett (2)
-
Mitchell Garrison (1)
-
Mitchell Smith (1)
-
Mithat Gonen (1)
-
mitomycin (1)
-
mitoxantrone (1)
-
MMed (1)
-
mmr (1)
-
mmr deficient (1)
-
MOAWIA MOHAMMED ALI ELHASSAN (1)
-
mobile app (1)
-
mobility (1)
-
modality therapy (1)
-
moderate-penetrance mutations (1)
-
Moffitt Cancer Care (1)
-
Moffitt Cancer Center (6)
-
MOHAMED ALORABI (1)
-
Mohammad Abu Zaid (1)
-
Mohammad K. Khan (2)
-
Mohammed Shimi (1)
-
molecular (1)
-
molecular analyses (1)
-
molecular analysis (3)
-
molecular biology (1)
-
molecular predictor (1)
-
molecular profiling (1)
-
molecular screening (2)
-
molecular subtypes (2)
-
molecular testing (2)
-
Molly MacDonald (1)
-
momelotinib (1)
-
monaleesa-7 (1)
-
MONARCH 2 (1)
-
Monash University (2)
-
Monica Bertagnolli (2)
-
Monica Morrow (2)
-
Monica Terenziani (1)
-
Monika Krzyzanowska (1)
-
Monique Hartley-Brown (1)
-
monoclonal antibodies (3)
-
monoclonal antibody (4)
-
monocytes (1)
-
monotherapy (5)
-
Montefiore Medical Center (2)
-
mood (1)
-
Moores Cancer Center (3)
-
MOR208 (1)
-
morbidity (1)
-
Morgan Romero (1)
-
mortality (3)
-
mortality rate (1)
-
Mothaffar Rimawi (1)
-
motolimod (1)
-
Mounika Addula (1)
-
Mount Sinai (2)
-
Mount Vernon Cancer Centre (1)
-
moxetumomab pasudotox (1)
-
MPH (1)
-
MPH; Jeff Summers (1)
-
mrcpc (1)
-
mrd (2)
-
MRI (3)
-
Mrinal Patnaik (2)
-
msi (1)
-
MSI mutation (1)
-
msi-h (1)
-
MSKCC (3)
-
MSLT2 trial (1)
-
mss (1)
-
Mt Sinai (1)
-
mTOR (1)
-
mTOR inhibitor (1)
-
mucositis (2)
-
Muhamad Alhaj Moustafa (1)
-
Muhamed Baljevic (1)
-
Muhammad Rafiqul Islam (2)
-
mulitcatheter brachytherapy (1)
-
multi fraction radiotherapy (1)
-
multicatheter interstitial brach (1)
-
multidisciplinary (3)
-
multidisciplinary care (1)
-
multidisciplinary health-care (1)
-
multikinase inhibitor (1)
-
multimodality (1)
-
multi-parametric (1)
-
multiple myeloma (55)
-
Multiple Myeloma (18)
-
MURANO (1)
-
MURANO trial (1)
-
MURIEL CUNNINGHAM (1)
-
Murray Brennan (5)
-
muscle (1)
-
muscle invasive (1)
-
muscle loss (1)
-
muscle mass (1)
-
muscle strength (1)
-
muscle-invasive (1)
-
muscle-invasive bladder cancer (5)
-
musculoskeletal symptom (1)
-
mutated pathways (1)
-
mutation burden (2)
-
mutations (2)
-
MYC (1)
-
MYC translocation (1)
-
mycophenolate mofetil (1)
-
myeloablative AHCT (1)
-
Myelodysplastic Syndomes (3)
-
myelodysplastic syndrome (9)
-
myelofibrosis (6)
-
myeloid growth factors (1)
-
myeloid neoplasms (1)
-
myeloma (8)
-
myeloma clones (1)
-
myeloproliferative neoplasms (2)
-
Myl-1401O. (1)
-
MyPathway trial (1)
-
N. Lynn Henry (1)
-
Nabiel Mir (1)
-
nab-paclitaxel (9)
-
NADA SULIMAN HAJ MUKHTAR (1)
-
Nadeem Abu-Rustum (1)
-
Nadia Harbeck (1)
-
Nadine Tung (1)
-
Nafisa Abdelhafiez (1)
-
Nagashree Seetharamu (2)
-
NAGI EL SAGHIR (1)
-
NAGI S. EL SAGHIR (1)
-
Nagi S. El-Saghir (2)
-
naive T cell depletion (1)
-
Naiyer Rizvi (2)
-
nala trial (2)
-
Namrata Vijayvergia (1)
-
Nancy Davidson (4)
-
Nancy Lin (3)
-
Nantes University Hospital (2)
-
Narjust Duma (1)
-
Narjust Florez (Duma) (1)
-
Narmin Talibova (1)
-
Natasha Leighl (1)
-
Natasha Stout (1)
-
Nathalie McKenzie (2)
-
Nathan Fowler (2)
-
Nathan Hale Fowler (1)
-
Nathan Pennell (1)
-
National Cancer Center Bejing (1)
-
National Cancer Center Hospital (1)
-
National Cancer Data Base (1)
-
National Cancer Database (2)
-
National Cancer Institute (14)
-
National Cancer Institute of Mil (1)
-
National Coalition for Cancer Research (1)
-
National Jewish Health (1)
-
national policy (1)
-
National Taiwan University (1)
-
natural killer cells (2)
-
nausea (6)
-
Naveen Pemmaraju (1)
-
Navneet Majhail (2)
-
Nawfel Mellas (1)
-
NCCN (64)
-
nccn 2020 (5)
-
NCCN 22nd Annual Conference (4)
-
nccn annual conference (6)
-
NCCN guidelines (11)
-
NCCN Hematologic Malignancies (19)
-
nccn, nccn annual conference, 4R model, pathways (1)
-
NCCTG N063H (1)
-
NCI (6)
-
NCI cancer center (2)
-
NCTN (1)
-
Neal Chawla (1)
-
Neal Meropol (3)
-
Neal Ready (1)
-
Neal Shore (1)
-
Nebraska Cancer Specialists (1)
-
Nebraska Medicine (1)
-
necitumumab (2)
-
neck dissection (1)
-
needle biopsy (1)
-
Neel U. Sukhatme (1)
-
Neeraj Agarwal (2)
-
Neil Canavan (4)
-
Neil Iyengar (2)
-
Neil Vasan (1)
-
NEJ026 trial (1)
-
nelipepimut-s (1)
-
Nelli Benjanyan (1)
-
Nelson Peralta (1)
-
Nengliang Yao (1)
-
neoadjuvant (3)
-
neoadjuvant chemotherapy (9)
-
neoadjuvant ipilimumab (2)
-
neoadjuvant radiation (1)
-
neoadjuvant therapy (8)
-
neoadjuvant treatment (6)
-
neoantigen (1)
-
neoantigen vaccine (1)
-
neoMONARCH (1)
-
neoMONARCH trial (1)
-
NEOSCOPE trial (1)
-
NeoSphere trial (1)
-
neotrip (1)
-
nephrectomy (8)
-
neratinib (3)
-
Netherlands Cancer Institute (5)
-
Netherlands Comprehensive Cancer (1)
-
NETs (1)
-
NETTER-1 (1)
-
NETTER-1 trial (1)
-
neuroblastoma (5)
-
neurocognitive (1)
-
neuroendocrine (1)
-
neuroendocrine disease (1)
-
neuroendocrine tumors (7)
-
neurologic side effects (1)
-
neurologic toxicity (1)
-
neuropathic pain (2)
-
neuropathy (5)
-
neurotoxicity (4)
-
neutropenia (3)
-
never smoker (1)
-
never smokers (2)
-
new mexico (1)
-
New York University (1)
-
newly diagnosed cancer patients (1)
-
NewYork-Presbyterian (1)
-
next generation sequencing (1)
-
next therapy (1)
-
next-generation sequencing (3)
-
nf1 (1)
-
NGS (6)
-
NHL (6)
-
Nicholas J. Vogelzang (1)
-
Nicholas James (5)
-
Nicholas Simon (1)
-
Nicholas Turner (5)
-
Nicolaus Kröger (1)
-
Nicole Kuderer (1)
-
Nicole Mittmann (1)
-
Nicole Shonka (1)
-
Nicolò Matteo Luca Battisti (1)
-
nicotinamide (2)
-
Nienke A. de Glas (1)
-
Nikhil Wagle (2)
-
nilotinib (2)
-
Nina Rosa Neuendorff (1)
-
Nina Shah (1)
-
nintedanib (1)
-
niraparib (8)
-
Nirupa Raghunathan (5)
-
Nita Ahuja (1)
-
Nithya Krishnan (2)
-
Nitin Jain (1)
-
Nitin Mehrotra (1)
-
nivolumab (49)
-
nivolumab dosing (1)
-
nivolumab monotherapy (3)
-
NIVOREN GETUG-AFU 26 (1)
-
NIZAR TANNIR (1)
-
nk cells (1)
-
NK1 inhibitor (1)
-
nodal irradiation (1)
-
nodal radiation (1)
-
nodal response (1)
-
node negative (1)
-
node-negative (5)
-
node-positive (2)
-
node-positive disease (1)
-
nodules (2)
-
Noelle LoConte (1)
-
non-bulky (1)
-
non-clear cell renal cancer (2)
-
noncolorectal GI cancers (1)
-
non-favorable AML (1)
-
Non-Hodgkin lymphoma (12)
-
nonmelanoma skin cancer (2)
-
non-melanoma skin care (2)
-
nonmetastatic (2)
-
non-muscle invasive (1)
-
non-muscle-invasive bladder canc (1)
-
nonpharmacological techniques (1)
-
nonseminoma (1)
-
non-small cell lung cancer (33)
-
non–small cell lung cancer (4)
-
nonsmoking-associated (1)
-
non-specific symptoms (1)
-
nonsquamous (3)
-
nonverbal (1)
-
Nora Janjan (2)
-
Nordwest Hospital (2)
-
NORMAN J. LACAYO (1)
-
Norman Sharpless (3)
-
Norman Wolmark (2)
-
Norris Cotton Cancer Center (1)
-
North Shore LIJ (1)
-
NorthShore University Health (1)
-
Northwestern (1)
-
Northwestern University (5)
-
novel agents (1)
-
novel combination (1)
-
novel drug targets (1)
-
novel pathways (1)
-
novel-novel (1)
-
n-Pacific Lymphoma 2016 (1)
-
NRG Oncology (6)
-
NRG Oncology/NSABP B-42 (2)
-
NRG Oncology/NSABP B-42 trial (1)
-
NRG Oncology/NSABP B-52 trial (1)
-
nrg/nsabp (1)
-
NRG/RTOG 0712 (1)
-
NSABB (1)
-
NSABP (2)
-
NSABP 35 (1)
-
NSABP B20 (1)
-
NSABP B-35 (1)
-
NSABP B-36 (1)
-
NSABP B-47 trial (1)
-
NSABP clinical trials (1)
-
NSCLC (69)
-
NSGO-PALEO / ENGOT-EN3 trial (1)
-
nursing homes coronavirus (1)
-
nut consumption (1)
-
NYU (2)
-
NYU Langone (2)
-
NYU Perlmutter Cancer Center (2)
-
OAK trial (2)
-
obamacare (1)
-
obesity (5)
-
obinutuzumab (11)
-
objective response (1)
-
observation (3)
-
OCE members (1)
-
Octreotate (1)
-
Octreotide (1)
-
Ogidiagba Louis Efe (1)
-
ogliometastatic (1)
-
ogliometastatic disease (1)
-
Ohio State University (3)
-
OhioHealth (2)
-
Ohiohealth Kobacker House (1)
-
Ola Landgren (3)
-
olanzapine (3)
-
olaparib (12)
-
olaratumab (1)
-
older cancer survivor (1)
-
older patients (11)
-
oligometastatic (5)
-
Oliver Sartor (4)
-
Olivier Casasnovas (4)
-
Olivier Chinot (1)
-
Olivier Tredan (1)
-
Ollie Minton (1)
-
Olufunmilayo I. Olopade (2)
-
OlympiAD trial (1)
-
omega-3 fatty acid (1)
-
Omid Hamid (2)
-
omitting surgery (1)
-
oncologic surgery (1)
-
oncologist partnering (1)
-
oncologist perception (1)
-
oncology (53)
-
oncology care (1)
-
Oncology Care Model (2)
-
oncology in India (1)
-
oncology in South America (1)
-
oncology in the Middle East (1)
-
oncology provider (1)
-
OncologyGo (4)
-
oncopolicy (1)
-
Oncotype DX (5)
-
online curriculum (1)
-
online patient information (1)
-
online tumor board (1)
-
oocyte (1)
-
OP-106 Horizon (1)
-
OpACIN trial (2)
-
open (1)
-
open resection (1)
-
open transthoracic (1)
-
operable cancer (1)
-
opiates (1)
-
opinion (4)
-
opiod prescribing (1)
-
opiod risk (1)
-
opioid (3)
-
opioid abuse (1)
-
opioid access (2)
-
opioid addiction (1)
-
opioid epidemic (1)
-
opioid reduction (1)
-
opioid use (1)
-
opioid use disorder (1)
-
opioid-associated death (1)
-
opioids (6)
-
opioids and cancer pain (1)
-
opportunity cost (1)
-
optimal sequencing (1)
-
OPTIMAL>60 study (1)
-
oral anticoagulants (2)
-
oral azacitidine (1)
-
oral cancer (1)
-
oral cavity (1)
-
oral chemotherapy (1)
-
oral HPV infection (1)
-
oral mucositis (1)
-
oral paclitaxel (1)
-
oral regimen (1)
-
Oregon (1)
-
Oregon Health & Science (1)
-
Oregon Health & Science Universi (1)
-
organ preservation (1)
-
oriole trial (1)
-
oropharyngeal (1)
-
oropharyngeal cancer (4)
-
Oscar B. Goodman (1)
-
OSCAR GUEVARA (1)
-
osimertinib (2)
-
osteoradionecrosis (1)
-
OSUCCC (1)
-
other-cause mortality (1)
-
Otis Brawley (1)
-
Ottawa Hospital Cancer Centre (1)
-
Otterson (1)
-
OUISSAM AL JARROUDI (1)
-
outcome (1)
-
outcomes (2)
-
outcomes analysis (1)
-
outcomes research (1)
-
out-of-pocket costs (1)
-
outpatient care (1)
-
outpatient treatment (1)
-
ovarian cancer (25)
-
ovarian failure (1)
-
ovarian function (2)
-
ovarian function suppression (2)
-
ovarian insufficiency (1)
-
ovarian suppression (7)
-
overall survival (22)
-
overall survival analysis (2)
-
overtreatment (2)
-
OVHIPEC trial (1)
-
Owen N. Witte (1)
-
Owen O'Connor (1)
-
oxaliplatin (13)
-
Oxford University (1)
-
oxybutynin (1)
-
oxygen (1)
-
p16 (1)
-
PAC (1)
-
pace-b trial (1)
-
PACIFIC trial (3)
-
paclitaxel (19)
-
pacritinib (1)
-
PADMA trial (1)
-
Padmanee Sharma (1)
-
pain (2)
-
pain assessment (2)
-
pain flare (1)
-
pain management (4)
-
Pain Management (2)
-
pain relief (2)
-
pain score (1)
-
painful bone metastases (1)
-
painkillers (1)
-
PAKT trial (1)
-
palb2 (1)
-
palbociclib (11)
-
PALLAS trial (1)
-
palliative (1)
-
palliative care (33)
-
Palliative Care (2)
-
palliative care clinicians (2)
-
palliative care in cancer (1)
-
palliative care integration (1)
-
palliative chemotherapy (1)
-
PALOMA (1)
-
PALOMA 3 (1)
-
PALOMA-1/TRIO 18 (1)
-
PALOMA3 (2)
-
palpable stage 3 melanoma (2)
-
Pam Kohl (1)
-
Pamela Kunz (1)
-
PAMELA trial (2)
-
Pan Pacific Lymphoma (16)
-
PANACEA (1)
-
pancreatic cancer (25)
-
Pancreatic Cancer (11)
-
pancreatic carcinoma (1)
-
pancreatic ductal adenocarcinoma (1)
-
pancreatic ductal carcinoma (1)
-
pancreatic resection (1)
-
pancreatic tumors (1)
-
pandemic (1)
-
panitumumab (1)
-
PANKAJ JANI (1)
-
panobinostat (1)
-
Pan-Pacific Lymphoma 2016 (17)
-
Paola Gaggiotti (1)
-
paola-1 (1)
-
paola-1/engot-ov25 trial (1)
-
Paoli Palmettes Institute (2)
-
Paolo Ascierto (2)
-
Paolo Strati (1)
-
papillary RCC (1)
-
papillary renal cell carcinoma (2)
-
Parameswaran Hari (3)
-
parents (1)
-
Parkland Health System (1)
-
Parminder Singh (1)
-
PARP inhibitor (9)
-
PARP inhibitors (4)
-
partial breast radiation (2)
-
partial breast re-irradiation (1)
-
partial-breast irradiation (1)
-
partnership (1)
-
Parvez Dara (4)
-
Pasi Jänne (2)
-
Pasi S. Jänne (2)
-
passenger mutations (1)
-
pathologic (1)
-
pathologic complete response (4)
-
pathology (1)
-
pathway (1)
-
pathways (5)
-
Pati Schembari (1)
-
patient advocacy (1)
-
patient advocate (3)
-
patient burden (1)
-
patient care (1)
-
patient communication (1)
-
patient costs (1)
-
patient counseling (1)
-
patient decision-making (1)
-
patient distress (1)
-
patient education (1)
-
patient engagement (1)
-
patient experience (1)
-
patient features (1)
-
patient feedback (1)
-
patient information (1)
-
patient navigation (2)
-
patient navigator (1)
-
patient outcomes (3)
-
patient perception (1)
-
patient perspective (1)
-
patient preference (2)
-
patient reported outcomes (3)
-
patient reporting (1)
-
patient safety (1)
-
patient satisfaction (1)
-
patient selection (2)
-
patient-centered cancer care (1)
-
patient-centered care (5)
-
patient-reported data (1)
-
patient-reported outcome (2)
-
patient-reported outcomes (7)
-
patient-reported surveys (1)
-
patient-reported symptoms (1)
-
patients (1)
-
Patricia Eifel (1)
-
Patricia Ganz (9)
-
Patricia Hurley (1)
-
Patricia J. Goldsmith (1)
-
PATRICIA trial (1)
-
Patrick Beauregard (2)
-
Patrick Boland (1)
-
Patrick Eck (1)
-
Patrick Forde (1)
-
Patrick M. Lynch (1)
-
Patrick Schoffski (1)
-
Patrick Schöffski (1)
-
patterns of care (1)
-
Paul A. Bunn Jr (3)
-
Paul Bunn (4)
-
Paul Chapman (1)
-
Paul Goss (1)
-
Paul Jacobsen (2)
-
Paul Kalanithi (2)
-
Paul Kluetz (2)
-
Paul M. Cinciripini (1)
-
Paul Nguyen (7)
-
Paul O'Gorman Leukaemia Research (1)
-
Paul Richardson (4)
-
Paul Weiden (1)
-
Pauline Funchain (1)
-
PAVLOS MSAOUEL (1)
-
payer (1)
-
payer perspective (1)
-
Paz-Ares (1)
-
pazopanib (5)
-
pbi (1)
-
PCORI (1)
-
PCP (1)
-
PCR (4)
-
PD-1 (3)
-
pd-1 blockade (4)
-
PD-1 combination therapy (1)
-
PD-1 inhibitors (2)
-
PD-1 monotherapy (1)
-
PD-1 therapy (1)
-
PD1-blockers (1)
-
PDAC (2)
-
PDC (1)
-
PDL1 (3)
-
PD-L1 (16)
-
PD-L1 immunotherapy (1)
-
PD-L1 inhibition (1)
-
PD-L1 positive (1)
-
PDL1 staining (1)
-
PDL1-blockers (1)
-
pd-l1-negative (1)
-
PD-L1-positive (2)
-
PDL2 expression (1)
-
pearl trial (1)
-
pediatric (2)
-
pediatric cancer (3)
-
pediatric chemotherapy (1)
-
pediatric leukemia (2)
-
pediatric oncology (3)
-
Pedram Razavi (1)
-
pegilodecakin (1)
-
pegph20 (1)
-
pelvic lymph node (1)
-
pelvic radiation (1)
-
pembrolizumab (48)
-
pemetrexate (1)
-
pemetrexed (3)
-
penile cancer (2)
-
Pennsylvania Hematology Oncology (1)
-
Pennsylvania Hospital (2)
-
peptide-paclitaxel conjugate (1)
-
peptides (1)
-
Pere Gascón (1)
-
performance measures (1)
-
perimenopausal (1)
-
periodontal disease (1)
-
perioperative (1)
-
perioperative chemotherapy (1)
-
peripheral blood stem cell (1)
-
peripheral blood stem cells (1)
-
peripheral neuropathy (1)
-
peripheral T cell lymphoma (3)
-
peripheral T-cell lymphoma (2)
-
peritoneal cancer (1)
-
peritoneal carcinoma (2)
-
peritoneal carcinomatosis (2)
-
peritoneal metastases (1)
-
Persephone trial (2)
-
PERSIST Trial (2)
-
personal doses (1)
-
personalized cancer care (1)
-
personalized medicine (6)
-
personalized treatment (2)
-
personalized vaccine (1)
-
pertuzumab (5)
-
PET (3)
-
PET CT (1)
-
PET scan (7)
-
Peter Bach (3)
-
Peter Clark (2)
-
Peter Greenberg (1)
-
Peter Hoskin (1)
-
Peter Johnstone (1)
-
Peter L.J. Naredi (1)
-
Peter MacCallum Cancer Centre (4)
-
Peter MacCallum Centre (3)
-
Peter Naredi (1)
-
Peter O'Donnell (1)
-
Peter Paul Yu (4)
-
Peter Shields (2)
-
Peter Watson (1)
-
Peter Yu (1)
-
Peter Wiernik (1)
-
Petros Grivas (1)
-
pfs (6)
-
Ph+ ALL (1)
-
phaedra trial (1)
-
PHARE trial (1)
-
pharmacogenomic (1)
-
phase 1 trials (1)
-
phase I clinical trial (1)
-
phase I trial (1)
-
PhD (2)
-
PhD; and Olexiy Kovalyov (1)
-
PhD; Iryna Kriachok (1)
-
PhD; Ivan Smolanka (1)
-
PhD; Jennifer J. Gao (1)
-
PhD; LAWRENCE N. SHULMAN (1)
-
PhD; Nataliia Dovganych (1)
-
PHIL FALKOWITZ (1)
-
philadelphia chromosome (1)
-
Philip A. Thompson (2)
-
Philip Bonomi (5)
-
Philip Champion (1)
-
Philip Kantoff (2)
-
Philip Salem (1)
-
Philip Stella (1)
-
Philippe Rochigneux (2)
-
Philippe Spiess (1)
-
Phillip Gray (1)
-
Ph-negative (1)
-
photon therapy (1)
-
physical activity (2)
-
physical experience (1)
-
physical function (1)
-
physical therapy (1)
-
physician burnout (1)
-
physician’s choice (1)
-
physician-assisted death (1)
-
physician-assisted suicide (1)
-
physician-led (1)
-
Physicians' Health Study (1)
-
PI3K (2)
-
PI3K inhibition (1)
-
PI3K inhibitor (2)
-
pictilisib (2)
-
PIK3CA (2)
-
Piyush Agarwal (1)
-
placebo effect (1)
-
PlanB trial (1)
-
plasma (1)
-
plasma cell leukemia (1)
-
plasma cell-free DNA (1)
-
plasma DNA (1)
-
plasmacytoma (1)
-
plasmamatch (1)
-
platelet transfusion (1)
-
platinum (1)
-
platinum chemotherapy (7)
-
platinum combination chemotherap (1)
-
platinum-based (1)
-
platinum-based chemo (1)
-
platinum-based chemotherapy (2)
-
platinum-ineligible (2)
-
platinum-resistant (2)
-
platinum-sensitive (4)
-
playwright (1)
-
PLD-1 (1)
-
plenary (1)
-
pneumonitis (2)
-
polatuzumab vedotin (2)
-
policy (3)
-
policy issues (2)
-
politics (2)
-
polo trial (1)
-
polybromo (1)
-
polycythemia vera (1)
-
polygenic risk scores (1)
-
polymerase epsilon mutation (1)
-
pomalidomide (2)
-
ponatinib (2)
-
Ponnandai S. Somasundar (1)
-
pooled data analysis (1)
-
poor prognosis (2)
-
poor response (1)
-
poor-prognosis (2)
-
poor-prognosis tumors (1)
-
poor-risk (1)
-
POSH study (1)
-
positive lymph nodes (2)
-
positron emission tomography (1)
-
positron emission topography (2)
-
postmenopausal (10)
-
postmenopausal breast cancer (4)
-
postmenopausal patients (1)
-
postmenopausal women (1)
-
postoperative radiation (2)
-
postplatinum (1)
-
post-remission (1)
-
postsurgery (1)
-
postsurgical (1)
-
postsurgical syndromes (1)
-
post-treatment care (1)
-
post-treatment services (1)
-
Prasad Adusumilli (1)
-
Prashant Kapoor (1)
-
precision medicine (7)
-
precision oncology (1)
-
predict survival (1)
-
predictive biomarker (2)
-
predictive biomarkers (1)
-
predictive factors (1)
-
prednisone (9)
-
Preety Narayan (1)
-
pregnancy (5)
-
premenopausal (6)
-
pre-menopausal (1)
-
premenopausal breast cancer (1)
-
premenopausal patients (1)
-
premenopausal women (1)
-
PREOPANC-1 (1)
-
preoperative (1)
-
preoperative chemotherapy (1)
-
preoperative exercise (1)
-
preoperative radiotherapy (1)
-
prescribing opioids (1)
-
presurgery (2)
-
pretreated (3)
-
pretreated colorectal cancer (1)
-
prevention (1)
-
previously treated lung cancer (1)
-
prexasertib (1)
-
PRIMA trial (1)
-
prima/engot-ov26/gog-3012 (2)
-
primary care (2)
-
primary care physician (1)
-
primary care provider (2)
-
primary glioma (1)
-
primary treatment (1)
-
primary tumor location (1)
-
primary tumors (1)
-
Primo Lara (1)
-
Princess Dina Mired (1)
-
Princess Margaret Cancer Centre (4)
-
Princess Margaret Hospital (5)
-
prior authorization (1)
-
Priscilla Brastianos (3)
-
procarbazine (1)
-
PRODIGE 24 (1)
-
PRODIGE 7 (1)
-
PRODIGY 12-ACCORD 18 (3)
-
Prof. Kouhen Fadila (1)
-
ProfilER study (1)
-
profound trial (1)
-
progestin (1)
-
prognosis (2)
-
prognostic (2)
-
prognostic awareness (1)
-
prognostic biomarker (2)
-
prognostic information (1)
-
prognostic model (1)
-
prognostic models (1)
-
prognostic stage (1)
-
prognostic uncertainty (1)
-
prognostication (1)
-
programmed cell death ligand 1 (1)
-
programmed cell death protein 1 (1)
-
progress (2)
-
progression-free survival (9)
-
progressive cancer (1)
-
project facilitate (1)
-
prolonged grief disorder (1)
-
PROMIS (1)
-
PROMIS group (1)
-
PROMISE trial (1)
-
proof of concept (1)
-
pros (3)
-
pros and cons (1)
-
PROSPER trial (2)
-
prostate (1)
-
prostate bed (1)
-
prostate cancer (98)
-
Prostate Cancer (26)
-
prostate cancer guidelines (1)
-
prostate cancer subclass (1)
-
prostate specific antigen (1)
-
prostatectomy (4)
-
prostate-specific antigen (3)
-
ProtecT (1)
-
PROTECT trial (1)
-
PRO-TECT trial (1)
-
proton beam radiotherapy (2)
-
proton therapy (3)
-
provider roles (1)
-
prudence francis (2)
-
PSA (5)
-
psychiatry and cancer (1)
-
psychological (1)
-
psychological experience (1)
-
psychological intervention (1)
-
psychological support (1)
-
psycho-oncology (1)
-
psychosocial (3)
-
psychosocial care (3)
-
psychosocial distress screening (1)
-
psychosocial services (1)
-
PTCL (3)
-
public health (1)
-
pyramid trial (1)
-
Qian Shi (1)
-
QMAP (1)
-
qol (5)
-
QTP (1)
-
QUADRA (1)
-
quadruplet (1)
-
quality (1)
-
quality assessment (1)
-
quality cancer care (2)
-
quality care (20)
-
quality care in cancer (1)
-
quality control (1)
-
quality improvement (3)
-
quality in cancer care (2)
-
quality measurement (1)
-
quality measures (1)
-
quality of care (3)
-
quality of life (33)
-
quality of life survivor (1)
-
quality reporting (1)
-
quality training (1)
-
quality-adjusted survival (1)
-
quazar trial (1)
-
Queen Elizabeth Hospital (1)
-
Queen Mary University of London (5)
-
quitting smoking (1)
-
Quyen Chu (2)
-
R. Angelo de Claro (2)
-
R. GREGORY BOCIEK (1)
-
Raamis Khwaja (1)
-
Rabin Medical Center (2)
-
race (2)
-
Rachel Freedman (1)
-
Rachel Grisham (1)
-
Rachel Joseph (1)
-
Rachel Lynn Yung (2)
-
Rachel Tompa (1)
-
Rachelle Bernacki (2)
-
racial disparities (2)
-
racial disparity (1)
-
RAD001 (1)
-
Radhakrishna Vemuri, Jo Cavallo (1)
-
RADIANT-4 (1)
-
radiation (10)
-
radiation boost (1)
-
radiation dose (1)
-
radiation fractionation (2)
-
radiation oncology (6)
-
radiation oncology service (1)
-
radiation therapy (14)
-
radical cystectomy (1)
-
radical prostatectomy (4)
-
radioactive iodine (1)
-
radioembolization (1)
-
radiographic pfs (1)
-
radioimmunotherapy (2)
-
radiology (1)
-
radiosurgery (2)
-
radiotherapeutic sensitivity (1)
-
radiotherapy (37)
-
radiotherapy deintensification (1)
-
radiotherapy delivery (1)
-
radiotherapy dose (1)
-
radiotherapy oral complications (1)
-
radiotherapy safety (1)
-
radium (1)
-
Radium 223 (1)
-
RADPAC trial (1)
-
Rafal Dziadziuszko (1)
-
Rafat Abonour (2)
-
RAINFALL trial (1)
-
Rajiv Pruthi (1)
-
Rajiv Shah (1)
-
Rakesh Chopra (5)
-
Ralph Hauke (2)
-
Ramaswamy Govindan (4)
-
Ramesh Ramanathan (1)
-
RAMI MANOCHAKIAN (1)
-
Ramu Kandasamy (1)
-
ramucirumab (4)
-
Rana McKay (7)
-
Randall Holcombe (1)
-
Randi Gould (3)
-
Randy Sweis (1)
-
Randy Wei (1)
-
range trial (1)
-
Ranjana Advani (1)
-
RANK lignad inhibitors (1)
-
Raphael E. Pollock (1)
-
rare cancers (1)
-
rare mutations (1)
-
rare tumors (2)
-
RARG coding variant (1)
-
RAS (2)
-
RAS wild type (1)
-
Rashmi Chugh (1)
-
RAS-mutation (1)
-
RATIFY trial (1)
-
RAVI AMARAVADI (1)
-
Ravi Mehrotra (2)
-
Ravindran Kanesvaran (1)
-
Rawad Elias (2)
-
Ray Page (1)
-
rbc (1)
-
RCC (25)
-
R-CHOP (7)
-
R-CHP (1)
-
REBECCA GLOMMEN (1)
-
Rebecca Johnson (2)
-
Rebecca Karp Leaf (1)
-
Rebecca Roy Thomas (1)
-
Rebecca Saracino (1)
-
RECORD 1 Trial (1)
-
record encounters (1)
-
rectal cancer (8)
-
rectal toxicity (1)
-
recurrence (6)
-
recurrence score (1)
-
recurrent cancer (2)
-
recurrent disease (1)
-
recurrent glioma (1)
-
recurrent head and neck cancer (1)
-
recurrent ovarian cancer (2)
-
red blood cell transfusion (2)
-
reduced high-dose volume radioth (1)
-
reduced intensity (2)
-
reducing opioid use (1)
-
reducing opioids (1)
-
reduse trial (1)
-
Reena A. George (1)
-
reflect study (1)
-
refractory (15)
-
refractory disease (6)
-
refractory Hodgkin lymphoma (1)
-
refractory mm (1)
-
refractory multiple myeloma (2)
-
Regine Nshimiyimana Maniraho (2)
-
regression-free survival (1)
-
rehabilitation (1)
-
reimbursement (2)
-
relapsed (12)
-
relapsed cancer (2)
-
relapsed disease (4)
-
relapsed mm (1)
-
relapsed multiple myeloma (2)
-
relapsed PTCL (1)
-
relapsed/refractory (2)
-
relapsed/refractory disease (2)
-
relaxation (1)
-
relay trial (1)
-
RELEVANCE trial (1)
-
remission (3)
-
Rena Conti (1)
-
renal cancer (4)
-
renal cell (1)
-
renal cell carcinoma (51)
-
Renata Urban (1)
-
RENEE MARIA SALIBY (1)
-
research (1)
-
research infrastructure (1)
-
resectable (2)
-
resectable cancer (2)
-
resectable gastric cancer (1)
-
resectable pancreatic cancer (1)
-
resected disease (1)
-
resected non small cell lung can (1)
-
resection (5)
-
Reshma Jagsi (2)
-
residual disease (2)
-
residual distant recurrence (1)
-
residual invasive disease (1)
-
resilience (2)
-
resistance mechanisms (2)
-
resistance pathways (1)
-
RESONATE-2 trial (1)
-
resource availability (1)
-
resources (1)
-
respiratory distress (1)
-
response rate (1)
-
response to treatment (1)
-
response-adapted chemotherapy (1)
-
restrictive prescribing (1)
-
ret fusion (1)
-
ret inhibitor (1)
-
retrospective (1)
-
Reverend Tawana Davis (1)
-
rhabdoid (1)
-
rhabdoid rcc (1)
-
rhabdomyosarcoma (1)
-
ribociclib (1)
-
Rich Rubenstein (1)
-
Richard A. Berjian (1)
-
Richard Ablin (2)
-
Richard Boxer (3)
-
Richard Brodkin (1)
-
Richard Cassidy (1)
-
Richard Champlin (1)
-
Richard E. Harris (1)
-
Richard Finn (4)
-
Richard Fisher (4)
-
Richard G. Abramson (1)
-
Richard Goldberg (3)
-
Richard Grenell (1)
-
Richard Herrmann (1)
-
Richard Hite (1)
-
Richard Hoppe (1)
-
Richard J. Boxer (18)
-
Richard L. Schilsky (1)
-
Richard Lee (1)
-
Richard Levine (1)
-
Richard M. Boulay (2)
-
Richard M. Stone (5)
-
Richard Margolese (4)
-
Richard Pazdur (9)
-
Richard S. Finn (1)
-
Richard Schilsky (7)
-
Richard Stone (9)
-
right side tumor (1)
-
right to try (2)
-
rigosertib (1)
-
Rigshospitalet (1)
-
Rimas Lukas (5)
-
Rinaa Punglia (1)
-
ring sideroblasts (1)
-
Rishi Surana (2)
-
rising costs (1)
-
risk assessment (1)
-
risk of death (2)
-
risk score (1)
-
risk status (1)
-
risk stratification (3)
-
rituximab (27)
-
rituximab follicular lymphoma (1)
-
rituximab maintenance (2)
-
rituximab-refractory (1)
-
rivaroxaban (1)
-
roar trial (1)
-
Robert A. Swarm (1)
-
Robert Bonney (1)
-
Robert Carlson (6)
-
Robert Chapman (1)
-
Robert Coleman (2)
-
Robert Croyle (2)
-
Robert Figlin (2)
-
Robert H. Lurie (3)
-
Robert Haddad (1)
-
Robert Harrison (1)
-
Robert J. Green (1)
-
Robert J. Jones (1)
-
Robert Kuske (2)
-
Robert L. Coleman (2)
-
Robert Livingston (1)
-
Robert Manges (1)
-
Robert Marcus (1)
-
Robert Miller (3)
-
Robert Motzer (2)
-
Robert Peter Gale (19)
-
Robert Rifkin (2)
-
Roberto Leon-Ferre (1)
-
Roberto Luksch (1)
-
Robin Hardbattle (1)
-
Robin Zon (1)
-
robot-assisted surgery (1)
-
robotic (1)
-
rocapuldencel-T (1)
-
Roger G. Lawrence (1)
-
Roger Henriksson (1)
-
Roger Rawlings (1)
-
Rogerio Lilenbaum (1)
-
Roisin Connolly (1)
-
Roland Seiler (2)
-
rolapitant (1)
-
role function (1)
-
Rolf Stahel (2)
-
Romain Cohen (1)
-
Romana (2)
-
Romano 1 (1)
-
Romano 2 (1)
-
romidepsin (1)
-
Ronald A. DePinho (8)
-
Ronald Blum (1)
-
Ronald Buckanovich (2)
-
Ronald Chen (3)
-
Ronald DePinho (1)
-
Ronald E. Turk (1)
-
Ronald Go (2)
-
Ronald Hoffman (1)
-
Ronald Maggiore (1)
-
Ronald Piana (880)
-
Ronit Leiba (1)
-
Rosa Nouvini (1)
-
Roswell Park (2)
-
rovalpituzumab tesirine (1)
-
Rova-T (3)
-
Rowan Chlebowski (4)
-
Roy Decker (2)
-
Roy Herbst (7)
-
Roy S. Herbst (1)
-
Royal Brompton Hospital (1)
-
Royal Marsden (1)
-
Royal Marsden Hospital (5)
-
Royal Marsden Hospital NHS Trust (1)
-
Royal Marsden NHS Foundation Tru (1)
-
Royal Marsden NHS Foundation Trust (1)
-
Rozalina G McCoy (1)
-
rpfs (1)
-
rt (1)
-
RTOG (3)
-
RTOG 0415 (4)
-
RTOG 0539 (1)
-
RTOG 0617 (2)
-
RTOG 9601 (3)
-
RTOG trial (1)
-
RTOG0521 (1)
-
Ruben A. Mesa (1)
-
Ruben Mesa (11)
-
rucaparib (2)
-
Rudiger Hehlmann (1)
-
Rujuta Saksena (2)
-
rural cancer care (1)
-
rural health care (2)
-
Rush Medical College (2)
-
Rush University Medical Center (3)
-
Rustam Tursun-Zade (1)
-
Rutgers Cancer Institute (2)
-
Rutgers University (1)
-
Ruth Etzioni (1)
-
Ruth Mary Parks (1)
-
Ruth O’Regan (1)
-
Ruth O'Regan (8)
-
ruxolitinib (1)
-
Rwanda (1)
-
Ryan Nguyen (1)
-
Ryan Rodriguez (1)
-
S. MONICA SONI (4)
-
S. Vincent Rajkumar (11)
-
s-1 (3)
-
Saad Usmani (6)
-
Saad Z. Usmani (1)
-
SABCS (2)
-
SABCS 2015 (31)
-
SABCS 205 (1)
-
Saber Boutayeb (1)
-
Sabin Russell (1)
-
Sabine Linn (1)
-
Sabine Siesling (2)
-
sabr (2)
-
SABR-COMET (2)
-
sacituzumab govitecan (2)
-
Safa El Kefi (1)
-
safe opiod disposal (1)
-
safe opiod storage (1)
-
safety (1)
-
safety in cancer care (1)
-
safety incidents (1)
-
Sagar Lonial (24)
-
SAID AFQIR (1)
-
Saitama Medical University International Medical Center (1)
-
Salah Osman (1)
-
Salah-Eddin Al-Batran (3)
-
salivary gland (1)
-
salivary glands (1)
-
Sally Luckett (1)
-
salvage management (1)
-
salvage radiation (1)
-
salvage radiation therapy (2)
-
salvage radiotherapy (2)
-
salvage therapy (1)
-
salvage treatment (1)
-
Sam Silver (3)
-
Sameer Mahesh (1)
-
Samer Khaled (1)
-
Samlau Kutana (1)
-
Samuel A. Kareff (1)
-
Samuel Chao (2)
-
Samuel Oschin Comprehensive Canc (1)
-
Samuel Rosner (1)
-
Samuel Rubinstein (1)
-
Samuel Silver (3)
-
Samuel Smith (1)
-
Samuel Stevens (1)
-
San Antonio Breast (54)
-
San Antonio Breast Cancer Sympos (67)
-
san antonio breast cancer symposium (1)
-
San Antonio Cancer Center (1)
-
San Camillo Forlanini Hospital (2)
-
San Raffaele Hospital (2)
-
Sandeep S. Arora (1)
-
Sandip Patel (1)
-
SANDPIPER (1)
-
Sandra Swain (1)
-
Sandra Wong (1)
-
Sandro Pignata (1)
-
Sandton Oncology Centre (1)
-
Sanjeev Arora (1)
-
SANTOSH RAO (1)
-
Santosshi Narayanan (1)
-
Saoussane Kharmoum (1)
-
Sapna Pradyuman Patel (1)
-
sar650984 (1)
-
Sara Christensen (1)
-
Sara Gafni (1)
-
Sara Hurvitz (3)
-
Sara Tolaney (2)
-
Sarah Bachmann (1)
-
Sarah Blair (1)
-
Sarah Brand (1)
-
Sarah Cannon Research Institute (2)
-
Sarah Goldberg (1)
-
Sarah Hoffe (1)
-
Sarah Holstein (3)
-
Sarah Hopkins (2)
-
Sarah Jackson (25)
-
Sarah Prinsloo (1)
-
Sarah Sammons (1)
-
Sarah Stream (1)
-
Sarah Weiss (1)
-
Sarah Yagerman (1)
-
Sarat Chandarlapaty (3)
-
sarcoma (2)
-
Sarcoma (3)
-
sarcomatoid (3)
-
sarcomatoid rcc (1)
-
sarcopenia (1)
-
Sarfraz Ahmad (1)
-
Sarina Isenberg (1)
-
Saro Armenian (1)
-
Satish Gopal (1)
-
Sattva Neelapu (1)
-
savolitinib (1)
-
SBRT (13)
-
scalp cooling (1)
-
SCALP trial (1)
-
SCLC (9)
-
score theory (1)
-
SCOT trial (1)
-
Scott Hamilton (1)
-
Scott Irwin (1)
-
Scott Kopetz (1)
-
SCOTT LITOW (1)
-
Scott Wilson (1)
-
screening (1)
-
screening eligibility (1)
-
Scripps Health (1)
-
Sean Smith (2)
-
Seattle Cancer Care Alliance (2)
-
Seattle Children’s Hospital (1)
-
Seattle Children's Hospital (1)
-
Sebastien Maury (2)
-
Sébastien Maury (1)
-
second cancer (1)
-
second cancers (1)
-
second opinions (1)
-
secondary cancers (1)
-
second-line therapy (4)
-
second-line treatment (3)
-
Sedan Dulgarian (1)
-
sedation (1)
-
Seema A. Khan (1)
-
Seema Bhat (2)
-
Seema Khan (2)
-
SEER database (2)
-
Sehn (1)
-
Seidman Cancer Center (1)
-
selecting treatment (1)
-
self-management (1)
-
Selina M. Luger (1)
-
Selma Schimmel (1)
-
semaphorin 4d (1)
-
seminoma (1)
-
sentinel nodes (1)
-
Seoul National U. Cancer Hospita (1)
-
Seoul National University Hospit (1)
-
Seppo Langer (1)
-
sequenced therapies (1)
-
sequencing agents (1)
-
sequencing therapy (4)
-
Sergey Kozhukhov (1)
-
Sergio Giralt (1)
-
serial (1)
-
serial care (1)
-
serious illness care (1)
-
serious ovarian cancer (1)
-
serous ovarian cancer (1)
-
serum cytokines (1)
-
serum-based biomarker (1)
-
Setting Tags (1)
-
sexual aids (1)
-
sexual function (2)
-
sexual gender minorities (1)
-
Shahrukh Hashmi (1)
-
Shailender Bhatia (2)
-
Shaji Kumar (5)
-
Shaker Dakhil (1)
-
Shakira Grant (3)
-
Shalmali Pal (13)
-
Shannon Coleman (1)
-
Shannon MacDonald (1)
-
Shannon Ugarte (2)
-
Shanta Boles (1)
-
Shanu Modi (2)
-
shared decision making (1)
-
Sharon Barger (1)
-
Sharon Berenfeld (1)
-
Sharon Donovan (1)
-
Sharyn Kurtz (1)
-
Shawn Amer (1)
-
Shawn Farrah (1)
-
Shawna Hudson (1)
-
Sheila Garland (1)
-
Sheila Leatherwood (1)
-
Sheila McGlown (1)
-
Sheila N. Garland (1)
-
Sheila Ross (1)
-
Shekinah Nefreteri Elmore (1)
-
Shelly Latte-Naor (5)
-
Sherene Loi (3)
-
Sheri Sobrato Brisson (1)
-
Sherri Rosenthal (1)
-
Shiao-Pei Weathers (1)
-
Shiliang Zhang (1)
-
Shilo Kramer (1)
-
Shira Klapper (1)
-
Shirlee Simpson (1)
-
Shirley Grandahl (1)
-
Shoshana Rosenberg (1)
-
Shou-Ching Tang (1)
-
Shradda Dalwadi (1)
-
Shreya Desai (1)
-
Shridar Genevan (1)
-
Shrinivas Rathod (1)
-
Shulian Wang (1)
-
Shumei Song (1)
-
Sian Pugh (1)
-
siblings (1)
-
Sibylle Loibl (3)
-
side effects (4)
-
Sideny Kimmel Cancer Center (1)
-
Sidney Kimmel Cancer Center (1)
-
Sidney Kimmel Comprehensive Canc (2)
-
Sidney Kimmel Comprehensive Cancer Center (1)
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University (1)
-
Sigrid Barklund (1)
-
Silvia Novello (2)
-
Silvio Monfardini (9)
-
Simon Cancer Center (1)
-
Simon Davies (1)
-
Simon Rule (2)
-
Simone Consulting Company (2)
-
Simone Koole (1)
-
Simron Singh (2)
-
Sincere McMillan (1)
-
Sindhuja Kadambi (1)
-
single fraction (1)
-
single-agent therapy (1)
-
single-dose radiotherapy (1)
-
single-gene test (1)
-
Sir Murray F. Brennan (2)
-
sirolimus (1)
-
SITC (22)
-
Siteman Cancer Center (1)
-
skeletal event (1)
-
skin cancer (25)
-
Skin Cancer (9)
-
skin toxicities (1)
-
sleep disturbances (1)
-
SLL (6)
-
SLNB-positive (1)
-
small cell lung cancer (10)
-
small lymphocytic leukemia (2)
-
small lymphocytic lymphoma (2)
-
small molecule inhibitors (1)
-
small-molecule inhibitor (1)
-
smart start (1)
-
smartphone app (1)
-
Smilow (1)
-
Smilow Cancer Hospital (3)
-
Smita Banerjee (1)
-
Smita Bhatia (4)
-
Smith Breast Center (1)
-
Smith Giri (1)
-
smoking (3)
-
smoking cessation (2)
-
smoldering myeloma (5)
-
So Yeon Kim (1)
-
social function (1)
-
soft tissue sarcoma (1)
-
SOFT trial (8)
-
soft-tissue sarcoma (2)
-
Sola Kim (1)
-
Solange Peters (2)
-
SOLAR trial (1)
-
SOLAR-1 (1)
-
solid cancers (1)
-
solid tumors (8)
-
Solid Tumors (4)
-
SOLO2 trial (2)
-
solo3 (1)
-
somatic mutation (1)
-
Somnath Mukherjee (2)
-
Sonali Smith (6)
-
Sonia Ray (1)
-
Sonja Vliek (1)
-
Sonja Zweegman (1)
-
Sophia Kustas Smith (1)
-
sophia trial (2)
-
sorafenib (10)
-
soritinib (1)
-
Sormain trial (1)
-
sotatercept (1)
-
South Texas Oncology and Hematology (1)
-
Southampton University Hospital (1)
-
Southwest Oncology Group (1)
-
spanish-speaking (1)
-
SPARTAN trial (1)
-
SPCG-13 trial (1)
-
sperm bank (1)
-
spinal cord compression (1)
-
spinal instability (1)
-
spinal lesions (1)
-
spinal metastases (1)
-
spleen (1)
-
splenectomy (1)
-
splenic volume (1)
-
splicing modulator (1)
-
sporadic breast cancer (1)
-
SPPORT trial (1)
-
squamous (2)
-
squamous carcinoma (1)
-
squamous cell (2)
-
squamous cell carcinoma (6)
-
squamous lung cancer (1)
-
squamous NCLC (2)
-
SQUIRE (1)
-
SQUIRE trial (2)
-
Srdan Verstovsek (1)
-
Srikala Sridhar (2)
-
Srinadh Komanduri (1)
-
Sriram Yennu (1)
-
St. Jude (2)
-
St. Jude Children's (1)
-
St. Jude Children's Research Hos (1)
-
St. Jude Family Advisory Council’s Subcommittee on Quality of Life and Palliative Care (1)
-
Stacey Berg (1)
-
Stacyann Bailey (1)
-
stage 4 (1)
-
stage data (1)
-
stage I (1)
-
stage I cancer (1)
-
stage I testicular cancer (1)
-
stage II (2)
-
stage II breast cancer (1)
-
stage III (1)
-
stage III breast cancer (1)
-
stage III cancer (1)
-
Stage III disease (1)
-
stage III melanoma (1)
-
stage IV disease (1)
-
stage IV lung cancer (2)
-
staging (1)
-
staging criteria (1)
-
staging quality (1)
-
STAMPEDE (1)
-
STAMPEDE trial (10)
-
Stan Winokur (2)
-
standard of care (2)
-
standard radiotherapy (1)
-
standard therapy (1)
-
Stanford (1)
-
Stanford Cancer Center (1)
-
Stanford Cancer Institute (5)
-
Stanford Health Care (1)
-
Stanford School of Medicine (1)
-
Stanford University (8)
-
Stanford University Medical Center (1)
-
Stanford University School of Me (1)
-
Stanley M. Marks (1)
-
STAR trial (1)
-
starting mammography age (1)
-
state of cancer care (3)
-
state of the art (1)
-
statins (1)
-
statistical analysis (1)
-
Stay With Me Awhile (1)
-
Stefan Ciurea (1)
-
Stefan Terwindt (1)
-
Stefano Signoroni (1)
-
stem cell transplant (2)
-
steml cell transplant (1)
-
step-care approach (1)
-
Stephan Stilgenbauer (4)
-
Stephanie Graff (2)
-
Stephanie Walker (1)
-
Stephen Ansell (5)
-
Stephen Chandler (1)
-
Stephen Chun (2)
-
Stephen Forman (2)
-
Stephen Fox (1)
-
Stephen Gottschalk (1)
-
Stephen Johnston (1)
-
Stephen R.D. Johnston (1)
-
Stephen Sagar (1)
-
Stephen Schuster (2)
-
Stephen Sonis (1)
-
step-wise guidance (1)
-
stereotactic (1)
-
stereotactic ablative radiation (3)
-
stereotactic body radiation ther (2)
-
stereotactic body radiotherapy (8)
-
stereotactic radiation (1)
-
Steven E. Vogl (6)
-
Steven Horwitz (4)
-
Steven Kalister (1)
-
Steven Le Gouill (2)
-
Steven Narod (1)
-
Steven Nurkin (1)
-
Steven Shak (1)
-
Steven Treon (1)
-
Steven Vogl (13)
-
stigma (1)
-
StiL trial (1)
-
STREAM (1)
-
strength training (1)
-
stress (2)
-
stress management (2)
-
stroma (1)
-
stromal tumor (1)
-
stromal tumor-infiltrating lymph (1)
-
structured reporting (1)
-
Stuart Lichtman (3)
-
Stuart M. Lichtman (12)
-
Subeera Khan (1)
-
subserosal (1)
-
substance use disorders (1)
-
subtypes (1)
-
SUCCESS A trial (1)
-
Sudhir Srivastava (2)
-
Sue Yom (1)
-
suffering (1)
-
suicide (3)
-
suicide ideation (1)
-
suicide risk (1)
-
Suleika Jaouad (1)
-
Sumanta Kumar Pal (1)
-
Sumanta Pal (11)
-
Sumit Agarwal (1)
-
Sumit Shah (1)
-
Suneel Kamath (1)
-
sunitinib (22)
-
sunitinib vaccine (1)
-
Sunnybrook Health Sciences Centr (1)
-
Sunnybrook Odette Cancer Centre (1)
-
support services (1)
-
supportive care (8)
-
Supportive Care (3)
-
Supriya Chopra (2)
-
Supriya Mohile (1)
-
Suresh Ramalingam (4)
-
Suresh S. Ramalingam (2)
-
surgery (6)
-
surgery volumes (1)
-
surgical cytoreduction (1)
-
surgical management (1)
-
surgical oncology (9)
-
surgical resection (1)
-
surgical site infection (1)
-
surgically resectable (1)
-
surgically resected patients (1)
-
surprise conversation (1)
-
surrogate endpoint (1)
-
survaxm (1)
-
surveillance testing (1)
-
survey (1)
-
surviellance therapy (1)
-
survival (7)
-
survival analysis (2)
-
survival in cancer (1)
-
survival rates (1)
-
survival registry (1)
-
survivin (1)
-
survivor (2)
-
survivorship (24)
-
Survivorship (3)
-
survivorship care (2)
-
survivorship provider (1)
-
survivorship standard (1)
-
survivorship-specific programs (1)
-
Susan Cohn (1)
-
Susan Falbo (1)
-
Susan Faye Dent (1)
-
Susan London (79)
-
Susan M. O’Brien (1)
-
Susan O’Brien (1)
-
Susan O'Brien (3)
-
Susan Reckling (23)
-
Susan Slovin (1)
-
Susan Swanson (1)
-
Susana Banerjee (1)
-
susceptibility (1)
-
Sushil Bhardwaj (1)
-
sustainable efforts (1)
-
Suzanna Zick (1)
-
Suzanne George (1)
-
Suzi Tortora (1)
-
Swedish Cancer Institute (1)
-
switch maintenance (1)
-
SWOG (3)
-
SWOG 0819 (1)
-
SWOG 1406 (1)
-
SWOG S0819 (1)
-
SWOG S0927 (1)
-
SWOG S1117 (1)
-
SWOG S9921 (1)
-
SWOG-8814 (1)
-
SWOGS0307 (1)
-
Syed (1)
-
Syed A. Abutalib (7)
-
Syed Abutalib (55)
-
Syed Ali Abutalib (68)
-
SYK/JAK (1)
-
Sylvester Comprehensive Cancer Center at the University of Miami (3)
-
Sylvie Leotin (1)
-
symptom assessment (1)
-
symptom burden (1)
-
symptom control (3)
-
symptom management (7)
-
Symptom Management (2)
-
symptom monitoring (1)
-
symptom reduction (1)
-
symptomatic relapse (2)
-
systemic chemotherapy (1)
-
systemic disease (1)
-
systemic therapy (5)
-
systemic treatment (1)
-
systems of care (1)
-
T cell (2)
-
T cells (5)
-
T. Ming Chu (1)
-
T1 tumors (1)
-
T1-2N0M0 (1)
-
T3 resectable cancer (1)
-
T790M mutation (1)
-
tags trial (1)
-
tailored therapy (1)
-
TAILORx (6)
-
Takeshi Kodaira (1)
-
Talal Hilal (1)
-
Talapro-2 (1)
-
talazoparib (1)
-
Talha Shaikh (1)
-
Tamim Niazi (1)
-
Tammie Denyse (1)
-
Tammy Schuler (2)
-
tamoxifen (16)
-
tamoxifen adherence (1)
-
Tamy Kim (2)
-
Tanya Dorff (1)
-
Tanya M. Wildes (1)
-
Tanya Spektor (1)
-
Tanya Wildes (1)
-
Taofeek Owonikoko (1)
-
tappas trial (1)
-
TAPUR (1)
-
Tara Henderson (2)
-
targeted agents (2)
-
targeted biologics (1)
-
targeted therapy (6)
-
targeted treatment (9)
-
targeted treatments (7)
-
taselisib (1)
-
Tata Memorial Centre (1)
-
Tata Memorial Hospital (2)
-
Tatiana Prowell (2)
-
Taussig Cancer Institute (1)
-
taxane (3)
-
taxol (1)
-
Taylor Bell Duck (1)
-
TBCRC 024 (1)
-
t-cell checkpoint (1)
-
T-cell therapy (1)
-
T-DM1 (5)
-
t-dxd (1)
-
TEAM IIb trial (1)
-
team management (1)
-
tecemotide (1)
-
technology (1)
-
tegafur (1)
-
telehealth (2)
-
telemedicine (1)
-
Temidayo Fadelu (1)
-
temozolomide (1)
-
temsirolimus (2)
-
Teresa Calimeri (2)
-
Teresa Pedersen (1)
-
terminal cancer (1)
-
Terri Coutee (1)
-
Terry Fry (1)
-
test (1)
-
testicular cancer (6)
-
testosterone suppression (1)
-
Texas A&M (1)
-
Texas Children's Hospital (1)
-
TEXT trial (2)
-
tgr-1202 (1)
-
TH3RESA trial (1)
-
Thaddeus Mason Pope (17)
-
The Angeles Clinic and Research (1)
-
The ASCO (1)
-
The ASCO Post (4155)
-
The ASCO Post Staff (5125)
-
The Christie NHS Foundation Trust (1)
-
the editors (1)
-
the mednet (1)
-
The Netherlands Cancer Institute (1)
-
The Ohio State University (5)
-
The Royal Marsden (2)
-
The Royal Marsden NHS Foundation (1)
-
The Royal Marsden NHS Foundation Trust (3)
-
The University of Chicago (1)
-
The University of Colorado (1)
-
The University of Manchester (2)
-
The University of Sydney (1)
-
The University of Texas MD Anderson Cancer Center (21)
-
The University of Texas Southwestern Medical Center (1)
-
The West Clinic (1)
-
Theodora Karnakis (1)
-
Theodore Lawrence (1)
-
Theodore Yaeger (1)
-
therapeutic response (1)
-
Therese Bevers (3)
-
Thierry Andre (1)
-
third generation inhibitors (1)
-
Thomas Abrams (1)
-
Thomas Buchholz (2)
-
Thomas D'Amico (2)
-
Thomas E. Witzig (1)
-
Thomas Goode (1)
-
Thomas J. Lynch Jr (1)
-
Thomas J. Roberts (1)
-
Thomas J. Smith (1)
-
Thomas Jefferson University Hosp (2)
-
Thomas LeBlanc (2)
-
Thomas Lester (1)
-
Thomas Powles (2)
-
Thomas Smith (1)
-
Thomas Stinchcombe (1)
-
thoracic cancer (2)
-
Thoracic Cancers Symposium (23)
-
thoracic malignancies (1)
-
thoracic radiation (1)
-
thoracic radiotherapy (1)
-
thoracic vertebral bodies (1)
-
thoracolaparoscopic (1)
-
thoracoscopic lobectomy (1)
-
thromboctyopenia (1)
-
thrombocythaemia (1)
-
thrombocytopenia (1)
-
thromboprophylaxis (2)
-
thrombosis (1)
-
thrombotic thrombocytopenic purp (1)
-
thymic epithelial tumors (1)
-
thyroid cancer (4)
-
Thyroid Cancer (1)
-
thyroid palpation (1)
-
Tia Higano (4)
-
Tiffany Fagnani (1)
-
Tiffany H. Williams (1)
-
TIGERx study (1)
-
TILs (3)
-
Tim Ahles (2)
-
TIM BARTHOLOW (1)
-
Tim Donald (2)
-
timely treatment (1)
-
Timothy Fenske (1)
-
Timothy Gilligan (2)
-
Timothy Murtha (1)
-
Timothy Quill (1)
-
Timothy S. Fenske (1)
-
Timothy Wilt (1)
-
Tina Marin (1)
-
Ting Bao (18)
-
tipiracil (1)
-
Tisch Cancer Institute (1)
-
titan trial (2)
-
tivo-3 trial (1)
-
tivozanib (1)
-
TK1 (1)
-
TK1 resistance (1)
-
TKI (7)
-
TKI resistance (1)
-
tkis (1)
-
tmb (1)
-
TNBC (13)
-
TNM staging (1)
-
TNT trial (2)
-
tobacco cessation (1)
-
Toby Campbell (1)
-
Todd Gibson (1)
-
Todd Palmby (1)
-
Todd Pickard (1)
-
Tom Baker Cancer Centre (1)
-
Tom Whitehead (1)
-
Tomma Hargraves (1)
-
Tommy Donbavand (1)
-
Toni Choueiri (16)
-
TONIC trial (1)
-
Tonie Forster (1)
-
Tony K.W. Hung (1)
-
Tony Mok (14)
-
Torben Plesner (2)
-
Tori Brunetti (1)
-
Toronto Sunnybrook Cancer Centre (1)
-
Toshihiko Doi (2)
-
total cancer care (1)
-
total neoadjuvant therapy (1)
-
toxicities (2)
-
toxicity (18)
-
toxicity burden (1)
-
Tracey Aiello (1)
-
Tracey Danaher (1)
-
Tracey Evans (1)
-
Tracy Balboni (1)
-
Tracy Batchelor (3)
-
trametinib (5)
-
transcend cll 004 (1)
-
TRANSCEND NHL 001 (1)
-
transitional cell carcinoma (1)
-
translational research (1)
-
transperineal radiation (1)
-
trastuzumab (18)
-
trastuzumab deruxtecan (2)
-
trastuzumab emtansine (4)
-
trastuzumab emtasine (1)
-
trastuzumab-resistant disease (1)
-
trasutuzmab (1)
-
Traver Hutchins (1)
-
trc105 (1)
-
treatment adherence (3)
-
treatment advances (1)
-
treatment burden (3)
-
treatment completion (1)
-
treatment deferment (1)
-
treatment deintensification (3)
-
treatment delays (1)
-
treatment disparities (1)
-
treatment duration (2)
-
treatment efficacy (1)
-
treatment errors (1)
-
treatment guidelines (1)
-
treatment intensification (1)
-
treatment modality (1)
-
treatment outcomes (2)
-
treatment paradigms (1)
-
treatment period (1)
-
treatment plan (1)
-
treatment plans (1)
-
treatment resistance (2)
-
treatment resistant (1)
-
treatment response (4)
-
treatment targets (1)
-
treatment toxicity (1)
-
treatment update (2)
-
treatment volume (2)
-
treatment-free remission (1)
-
treatment-naive (1)
-
treatment-naïve (4)
-
treatment-refractory (1)
-
tree nuts (1)
-
tremelimumab (1)
-
Trent Tipple (1)
-
trial enrollment (2)
-
trifluridine (1)
-
trigger (1)
-
trimodality therapy (1)
-
triple negative breast cancer (2)
-
triple-negative breast cancer (30)
-
triplet (1)
-
triplet regimen (1)
-
Tristana Vásquez (1)
-
TRK fusion (1)
-
tropomyosin receptor kinase inhi (1)
-
TRUS biopsy (1)
-
tucatinib (1)
-
Tulane (2)
-
Tulane Cancer Center (1)
-
Tulane University (1)
-
tumor biology (1)
-
tumor boards (1)
-
tumor complexity (1)
-
tumor gene expression (1)
-
tumor infiltrating lymphocyte (1)
-
tumor location (1)
-
tumor microenvironment (2)
-
tumor mutational burden (2)
-
tumor profiling (4)
-
tumor proportion score (3)
-
tumor response (1)
-
tumor sidedness (2)
-
tumor treating fields (1)
-
tumor-infiltrating lymphocytes (2)
-
tumors (1)
-
Tuya Pal (1)
-
Ty Higuchi (1)
-
Tycel Phillips (1)
-
Tyler Stewart (1)
-
tyrosine kinase inhibitor (11)
-
U Alabama at Birmingham (1)
-
U Alabama Cancer Center (1)
-
U Colorado Cancer Center (1)
-
U Colorado Health Science Center (1)
-
U Michigan Cancer Center (1)
-
UAB Comprehensive Cancer Center (1)
-
ublituximab (2)
-
UC Davis (1)
-
UC Irvine (2)
-
UC San Diego (4)
-
UC San Diego Moores (1)
-
UC San Francisco (6)
-
UCLA (12)
-
UCLA David Geffen School of Medicine (2)
-
UCLA Fielding School of Public Health (1)
-
UCLA Jonsson (3)
-
UCLA Medical Center (3)
-
UCSD (2)
-
UCSF (5)
-
UCSF Helen Diller (1)
-
Ugo Pastorino (2)
-
Ujwal Yanala (1)
-
ulcerative colitis (1)
-
ultra-high risk relapsed/refract (1)
-
ultrasensitive detection (1)
-
Umberto Vitolo (1)
-
Umbraco (1)
-
umbrella study (1)
-
Umea University Hospital (1)
-
UNC (3)
-
UNC Chapel Hill (4)
-
UNC health care (1)
-
UNC School of Medicine (1)
-
underserved (1)
-
underserved cancer patients (1)
-
underserved populations (1)
-
undertreatment (1)
-
unequal survival (1)
-
unilateral (1)
-
unilateral breast cancer (1)
-
Union for International Cancer Control (1)
-
UnitedHealth Group (1)
-
UnitedHealthCare (2)
-
Universitaetsklinikum des Saarla (1)
-
University Clinic of Navarra (3)
-
University College London (2)
-
University Hospital Basel (1)
-
University Hospital Erlangen (1)
-
University Hospital Essen (2)
-
University Hospital Heidelberg (1)
-
University Hospital Hôtel-Dieu (1)
-
University Hospital Leuven (1)
-
University Hospital of Lille (2)
-
University Hospital Zurich (1)
-
University Hospitals Gasthuisber (1)
-
University Hospitals Leuven (3)
-
University Medical Center Gronin (1)
-
University of Alabama at Birming (2)
-
University of Alabama Birmingham (4)
-
University of Alberta (1)
-
University of Amsterdam (1)
-
University of Arizona (1)
-
University of Athens (1)
-
University of Barcelona (2)
-
University of Basel (1)
-
University of British Columbia (5)
-
University of Calgary (1)
-
University of California (2)
-
University of California Irvine (1)
-
University of California San Die (2)
-
University of California San Francisco (3)
-
University of Cambridge (1)
-
University of Chicago (11)
-
University of Colorado (3)
-
University of Colorado at Denver (1)
-
University of Colorado Cancer Ce (1)
-
University of Edinburgh (1)
-
University of Florida (1)
-
University of Gothenburg (1)
-
University of Greifswald (2)
-
University of Illinois Chicago (1)
-
University of Iowa Carver College of Medicine (1)
-
University of Iowa Hospital (1)
-
University of Kentucky (1)
-
University of Lausanne (2)
-
University of Leeds (2)
-
University of Liverpool (1)
-
University of Manitoba (1)
-
University of Maryland (1)
-
University of Maryland Medical C (1)
-
University of Maryland Medical Center (1)
-
University of Memphis (1)
-
University of Miami Health Syste (1)
-
University of Michigan (8)
-
University of Michigan Health Sy (2)
-
University of Milan (1)
-
University of Minnesota (3)
-
University of Montreal (2)
-
University of Nantes (1)
-
University of Nebraska (7)
-
University of Nebraska Medical (5)
-
University of Nebraska Medical C (7)
-
University of Nebraska Medical Center (3)
-
University of New Mexico (2)
-
University of New South Wales (1)
-
University of North Carolina (16)
-
University of North Carolina Lineberger Comprehensive Cancer Center (1)
-
University of Paris Sud (1)
-
University of Pennsylvania (12)
-
University of Pittsburgh (2)
-
University of Queensland (1)
-
University of Rochester (1)
-
University of Rochester Medical Center (1)
-
University of San Diego (1)
-
University of South Carolina (1)
-
University of Southampton (3)
-
University of Southern Californi (1)
-
University of Sydney (3)
-
University of Texas (1)
-
University of Texas MD Anderson (1)
-
University of Torino (4)
-
University of Toronto (1)
-
University of Tubingen (2)
-
University of Tuebingen (2)
-
University of Turin (1)
-
University of Ulm (1)
-
University of Warwick (1)
-
University of Washington (10)
-
University of Washington Seattle (1)
-
University of Wisconsin (6)
-
University of Wisconsin Carbone (2)
-
University Paris Descartes (1)
-
University Paris-Sud (1)
-
UNMC (3)
-
unrelated HCT (1)
-
unresectable (2)
-
unresectable bladder cancer (1)
-
unresectable disease (1)
-
untreated RCC (1)
-
upfront surgery (1)
-
upfront therapy (1)
-
upfront treatment (1)
-
UPMC Hillman Cancer Center (1)
-
upper gastrointestinal cancer (1)
-
upstaging (1)
-
Uqba Khan (1)
-
uracil (1)
-
urban setting (1)
-
urethral cancer (1)
-
urinary tract cancer (1)
-
urogenital cancers (1)
-
urologic surgery (1)
-
Uroosa Ibrahim (1)
-
urothelial (1)
-
urothelial cancer (12)
-
urothelial carcinoma (11)
-
Ursula A. Matulonis (3)
-
Ursula Matulonis (3)
-
Ursula Sansom-Daly (2)
-
US Food and Drug Administration (2)
-
US Intergroup (1)
-
US Preventive Services Task Forc (1)
-
USC (3)
-
USC Norris (4)
-
USC Norris Cancer Center (4)
-
USC Norris Comprehensive Cancer Center (1)
-
Usha Menon (1)
-
usual care (1)
-
UT Health (1)
-
UT Health San Antonio Cancer Center (1)
-
UT Health Science Center (1)
-
UT Southwestern Medical Center (2)
-
uterine cancer (1)
-
UTSW (1)
-
UV exposure (2)
-
vaccine (3)
-
vacuum-assisted (1)
-
vadastuximab talirine (2)
-
Vadim Gushchin (1)
-
Vaishali Sanchorawala (1)
-
Vali Papadimitradopoulou (1)
-
Vali Papadimitrakopoulou (2)
-
Valisia LeKae (1)
-
Vall d'Hebron University Hospita (2)
-
value (2)
-
value in cancer care (3)
-
value in medicine (1)
-
value-based care (2)
-
Vamsidhar Velcheti (2)
-
Vanderbilt (1)
-
Vanderbilt Ingram (3)
-
Vanderbilt University (5)
-
Vanessa Eaton (1)
-
vaping (1)
-
variation in quality (1)
-
Vassiliki Papadimitrakopoulou (2)
-
VEGF (1)
-
VEGF blockade (1)
-
VEGF inhibitor (1)
-
Vejle Hospital (1)
-
velia/cog-3005 (1)
-
Velindre Hospital (1)
-
veliparib (7)
-
velipatib (1)
-
vemurafenib (3)
-
venetoclax (8)
-
venetoclax monotherapy (1)
-
venous thromboembolism (4)
-
Vered Stearns (3)
-
VHL (1)
-
Vicki Jackson (2)
-
Vicki Morrison (1)
-
Victor Vogel (2)
-
video tool (1)
-
vigil (1)
-
VIJAYA RAJ BHATT (1)
-
Vinay Prasad (1)
-
vinblastine (2)
-
Vincent DeVita (1)
-
Vincent Rajkumar (1)
-
vincristine (2)
-
vinflunine (3)
-
Vinicius Ernani (1)
-
vinorelbine (2)
-
viral reactivation (1)
-
Virginia Anderson (2)
-
Virginia Commonwealth University (1)
-
Virginia Kaklamani (1)
-
Vishal Bhatnagar (1)
-
Visionary Leader Award (1)
-
vitamin D (2)
-
Vivek Agarwala (1)
-
Viviane Hess (1)
-
VOLKER DIEHL (1)
-
vomiting (3)
-
Von-Hippel Lindau (1)
-
vorinostat (2)
-
Vratislav Strnad (1)
-
VTE (3)
-
vulvar cancer (2)
-
W. Marston Linehan (1)
-
W. Robert Lee (3)
-
Wafik El-Deiry (1)
-
Waldenström’s (1)
-
Waldenström’s Macroglobulinemia (1)
-
Walter Curran Jr (1)
-
Warren Mason (1)
-
Warwick Medical School (1)
-
Washington University (2)
-
Washington University School of Medicine in St. Louis (1)
-
watch and wait (1)
-
Watson for Oncology (1)
-
Wayne Kuznar (2)
-
wbi (1)
-
WBRT (3)
-
WCLC 2015 (24)
-
wealth expenditure (1)
-
wearable sensors (1)
-
web-based intervention (1)
-
web-based tool (1)
-
weight loss (4)
-
weight-based doses (1)
-
weight-loss intervention (1)
-
Weijing Sun (1)
-
Weill Cornell Medical College (2)
-
well follow-up (1)
-
well tolerated (1)
-
Wendy Demark-Wahnefried (1)
-
Wendy Harpham (2)
-
Wendy Lichtenthal (3)
-
Wendy Selig (1)
-
Wendy Vogel (5)
-
Wendy Wing-Lok Chan (1)
-
West Cancer Center (3)
-
West Clinic (1)
-
WHI (1)
-
white blood cell growth factor t (1)
-
white patients (2)
-
who (1)
-
WHO classification (1)
-
whole brain radiation (1)
-
whole brain radiotherapy (1)
-
whole breast radiation therapy (3)
-
whole exome sequencing (2)
-
whole genome profiling (1)
-
whole-brain radiotherapy (1)
-
whole-breast irradiation (1)
-
wild type (1)
-
wild-type (2)
-
wild-type KRAS (1)
-
William Aronson (1)
-
William Breitbart (12)
-
William Catalona (1)
-
William Curry (3)
-
William Dale (1)
-
William Gradishar (7)
-
William H. Redd (1)
-
William H. Sharfman (1)
-
William Hall (1)
-
William J.M. Hrushesky (1)
-
William M. Grady (1)
-
william m. sikov (2)
-
William McGivney (2)
-
William Meyer (1)
-
William N. Harwin (1)
-
WILLIAM OH (1)
-
William S. Shimp (3)
-
William Sikov (3)
-
William Tew (1)
-
William Travis (2)
-
William Wierda (3)
-
Wilms tumor (2)
-
Winship Cancer Institute (3)
-
Wolfgang Wick (1)
-
women (2)
-
Women and Infants Hospital of Rh (1)
-
women cancer survivors (1)
-
women in oncology (2)
-
Women Who Conquer Cancer (2)
-
Women's Health Initiative (2)
-
Women's Health Initiative Dietar (1)
-
workflow (1)
-
workforce development (1)
-
workplace stress (1)
-
workshop (1)
-
World Health Organization (1)
-
Wui-Jin Koh (2)
-
WUSTL (1)
-
www.reimagine.me (1)
-
Wyndham H. Wilson (1)
-
Wyndham Wilson (2)
-
Xin Gao (1)
-
Xin Zheng (1)
-
Xuesong Han (1)
-
Y537S mutation (1)
-
Yale Cancer Center (9)
-
Yale Law (17)
-
Yale School of Medicine (3)
-
Yale School of Nursing (1)
-
Yale University (2)
-
Yale University School of Medicine (1)
-
YANIN CHAVARRI-GUERRA (1)
-
Yen Nien (Jason) Hou (6)
-
Yen Nien Hou (5)
-
Yesne Alici (1)
-
Ying Taur (1)
-
yoga (1)
-
Yoli Origel (1)
-
Yonsei Cancer Center (1)
-
Yoon-Koo Kang (2)
-
young adult cancer (3)
-
young adult cancer survivor (1)
-
young adult oncology (2)
-
young adults (2)
-
young breast cancer (1)
-
young breast cancer patients (1)
-
young breast patients (1)
-
young cancer patients (1)
-
young patients (2)
-
young patients at end of life (1)
-
young women (1)
-
younger patients (3)
-
Yousuf Zafar (1)
-
Yulia Raskina (1)
-
Yung-Jue Bang (1)
-
Z. Kevin Liu (1)
-
Z11 study (1)
-
Zaina Qureshi (3)
-
Zelenetz (1)
-
Zeynep Zengin (1)
-
Zhongxing Liao (2)
-
Zineb Benbrahim (1)
-
ZINEB DAHBI (1)
-
Zofia Piotrowska (1)
-
zoledronic acid (1)
-
ZUMA-1 (1)
-
ZUMA-1 trial (1)